Designer peptide markers towards multifunctional nanoprobes for cellular targeting at the nanoscale. by Rakowska, PD
  
 
1 
 
 
Designer peptide markers towards multifunctional 
nanoprobes for cellular targeting at the nanoscale 
 
 
 
Paulina Dominika Rakowska 
 
 
 
Department of Chemistry 
University College London 
& 
Bioengineering  
National Physical Laboratory, UK 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted for the degree of 
Doctor of Philosophy at the University College London 
 
 
June 2014 
  
 
2 
 
  
  
 
3 
 
The work presented in this thesis is my own. Where information has been obtained 
from other sources, this has been clearly indicated in the methodology section of 
the thesis. 
Paulina D. Rakowska 
  
  
 
4 
 
  
  
 
5 
 
ACKNOWLEDGMENTS 
I would like to thank my supervisors, Dr Maxim Ryadnov from National Physical 
Laboratory and Dr Stefan Howorka from UCL for their guidance throughout this 
project.  I would like to acknowledge everyone, who contributed to this research 
with their work, expertise and advice – big ‘thank you’ to Eleonora Cerasoli, Santanu 
Ray, Mateusz Szymanski, Lloyd Ryan, Angelo Bella, Haibo Jiang, Jascindra Ravi, Alice 
Payne, Bill Cooley, Mark Turmaine and Prof. Chris Grovenor. I would like to thank 
Prof. Ian Gilmore for being such a wonderful friend. I am grateful to my partner 
Mariusz for his love and support. Finally, the biggest ‘thank you!’ to Baptiste 
Lamarre – a true scientist, for his enthusiasm, curious spirit and never-ending 
willingness to listen, discuss and help.     
  
  
 
6 
 
  
  
 
7 
 
ABSTRACT 
The project investigated the development of peptide-based nanotools for 
applications in cell biology. Differential intracellular and membrane targeting was 
probed using rationally designed cell penetrating and antimicrobial peptides.  
The interaction of the peptides with bacterial and mammalian membranes 
was imaged using a combination of atomic force microscopy (AFM) and high-
resolution secondary ion mass spectrometry (NanoSIMS). This approach provided 
unique information on the topography of peptide-treated membranes, obtained 
from AFM images, suggesting membrane changes as a result of peptide structuring 
and pore formation. The data was complemented by chemical imaging performed 
on the same samples with NanoSIMS, which revealed the precise localisation of 
peptide molecules in the membranes.  
In parallel, multidimensional protocol for tag-free quantification of cellular 
uptake of cell penetrating peptides, based on chromatographic separations and 
followed by isotope dilution mass spectrometry was developed.  The amount of the 
designed peptide, internalised by human dermal fibroblasts was evaluated and 
compared to the uptake of a broadly studied and well characterised naturally 
occurring peptide. The results were compared to the peptide uptake quantified 
using confocal fluorescence microscopy.   
The studied synthetic peptides were also investigated as model systems to 
functionalise metallic nanoparticles (NPs). Characterisation and functionalisation of 
the NPs were carried out. To prevent a non-specific physisorption of molecules, the 
surface of NPs was passivated by coating with lipid bilayer or polyethylene glycol. 
Finally, using cross-linking chemistry, the designed peptides were conjugated to the 
coated particles and their interaction with mammalian and microbial cells was 
investigated by transmission electron microscopy. 
The results of this work indicate that rationally designed peptides carry the 
potential for being employed in the development of nanoscale, multifunctional 
probes for differential and specific intracellular and extracellular targeting. 
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SA          Sinapinic Acid 
SEC         Size Exclusion Chromatography 
SIMS     Secondary Ion Mass Spectrometry 
SMCC              Succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate 
Sulfo-SMCC   Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
TCEP     Tris(2-carboxyethyl)phosphine 
TEM     Transmission Electron Microscopy 
TFA         Trifluoroacetic Acid 
UV Vis    Ultraviolet and Visible  
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  CHAPTER 1
BACKGROUND 
This chapter is based on extracts from two review articles: (1) “Peptidome analysis: 
tools and technologies”; P D Rakowska, M G Ryadnov in Amino Acids, Peptides and 
Proteins; E Farkas, M G Ryadnov; RSC Publishing 2013, 38, 172-202; and (2) “Nano-
enabled biomarker discovery and detection”; P D Rakowska and M G Ryadnov; 
Biomarkers in Medicine, 2011, 5(3), 387-96. Full versions of the articles can be 
found in ‘Publications from the project’ section of this thesis.  
1.1. Introduction 
In the era of ‘-omics’ strategies the information that can be obtained from the 
peptide content of biological systems has become of a great importance. The 
peptidome of a cell, tissue or even entire organism comprises all kinds of peptides, 
which occur either as ‘stand-alone’, functional species such as growth factors, 
hormones or metabolic products originating from protein precursors, or are 
products of metabolic processes and proteolytic degradation.  
Peptidomics presents an area of thorough, comprehensive and systematic 
qualitative and quantitative analyses of peptides. The analyses are varied and 
include peptide identity, quantity, structure and function. They span from simplest 
biochemical methods to advanced multidimensional separations and 
bioinformatics-empowered mass spectrometry.  
Peptides can serve as biomarkers but can also be used as templates in chemical 
biology for creation of novel peptide-based tools. The acquired knowledge, together 
with recent advancements in nanotechnology, provides opportunities to establish 
novel, sensitive, and selective methods for a wide range of bioanalytical platforms.  
Below is a brief overview of well-established peptidomic processing and 
introduction to tools, methods and approaches for the characterisation of peptides 
from biological media. Particular attention is given to the development of 
nanotechnology-enabled platforms for peptide analyses as well as synthetic 
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peptides as a means for constructing specially engineered tools for peptide-
mediated cellular targeting.  
1.2. Naturally occurring peptides 
Peptides present the most abundant class of molecules in biological systems. They 
can be defined as amino-acid assemblies, which contain no more than around 50 
amino-acid residues and with molecular weights up to 8 kDa.1 These low-molecular 
weight bio-regulators are critical to many biomolecular processes. 
Naturally biosynthesised peptides can be divided in to two classes: (1) Protein 
precursor derived peptides, formed in all organisms by proteolysis and subsequent 
posttranslational modifications, such as acylation, amidation or epimerisation of 
inactive protein precursors;2-5 (2) Those that are produced by synthetases,6-8 
specialised enzymes, that use amino- or hydroxyl-acid building blocks, which allows 
for the incorporation of unusual amino-acid residues, into the peptide structure, 
that are not encoded genetically.9, 10  
Each tissue consists of a limited set of peptide compounds. Also, the content 
of protein components in the tissue shows relative specificity of proteolysis. 
The proteolysis of protein sets of a given tissue will result in a large group of 
peptides, defined as a “tissue-specific peptide pool.”11, 12  
Research shows that extensive number of a given pool components can 
present noticeable activity both in vitro and in vivo. This points to the potential 
regulatory role of peptides in an organism. Generally, there is hardly a process that 
does not involve a presence or could not be influenced by a peptide.13  Also, 
the peptide composition undergoes changes as a result of tissue pathology, stress 
impact, treatment with drugs or genetic modifications. Based on the above, the 
thorough understanding of the effects on the peptide pools, caused by 
malfunctioning biological systems becomes extremely vital. As a result, 
the biological potential of peptides attracts an increasing attention in academia and 
industry and prompts the continuous development of new strategies and tools to 
enable peptidomic analysis of specific biological matrices.  
Peptides can provide excellent biomarkers. This is the case even when their 
biological activity is unambiguous or not apparent. Being mere products of 
proteolytic degradation peptides can be indicative of a particular pathology or 
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a developing process, whilst being highly specialised molecules they can possess 
different functions at different levels of molecular recognition and organismal 
development. For example, antimicrobial peptides (AMPs), which are evolutionarily 
conserved host defence effector molecules, not only can recognise and kill 
microorganisms but also elicit immunomodulatory effects and serve as stand-alone 
protein transduction domains. AMPs have been shown to play inhibitory and 
mediatory roles in combating and containing various disorders ranging from atopic 
dermatitis,14, 15 inflammations16-18 and wound healing19, 20 to autoimmunity21, 22and 
cancers.23-26 
1.3. Synthetic peptides  
Peptides can be seen as unique and powerful chemical tools. It is not only due to 
the natural diversity of amino-acid building blocks, but also due to the different 
types of modifications that are possible at an individual residue level.27  
As opposed to proteins, peptides are relatively easier to work with as they do 
not pose a higher order or complex secondary structures. Therefore, virtually 
complete exposure of their reactive groups to solvent is possible. This allows for 
straightforward modifications of the reactive sites, such as group-specific labelling 
or for chemical depletion approaches. These modifications can affect the chemical 
structure of a peptide, its conformation and activity. Being able to introduce post 
translational and chemical modifications to the peptides makes their use very 
attractive in the entire range of biology-based research.27  
 It is possible, nowadays, to chemically synthesise complete, functional peptides 
such as hormones or antibiotics. The development of synthetic peptides can be, for 
example, used to create novel, alternative diagnostic assays, such as the widely 
used peptide microarrays (peptide chips)28, 29 or as the one described by Real-
Fernández et al.30, who produced ferrocenyl glycopeptides, which can be used as 
electrochemical probes to characterise autoantibodies as biomarkers of multiple 
sclerosis, demonstrating that the autoantibodies are detectable with sensitivity 
comparable to ELISA methods. Here synthetic peptides are not targeted biomarkers 
as it would be for endogenous peptides but rather an auxiliary means for 
the detection and capture of other biomarkers, be these proteins, lipids or 
carbohydrates. Given that capturing peptides act as baits or epitopes and are 
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usually displayed on surfaces or used as conjugates with molecular reporters, their 
role in peptidome analyses is that of a probe. This type of probe can be defined as 
a known entity with known specific function, deliberately introduced into 
a peptidome to target and reveal a molecular mechanism or endogenous biomarker 
or to capture and help isolate the latter.  
Uses of peptide-based probes and tools are various and include targeted drug 
and gene delivery,31, 32 antimicrobials, neurodegenerative and neuroendocrinology 
research, regenerative medicine and synthetic biology.174, 175 The main challenge 
facing scientists in this field is to be able to rationally design peptides in order to 
gain control over their physical properties. This requires detailed understanding of 
the intended application as well as depth knowledge of the peptide at its all length 
scales.  
One of the most efficient approaches in synthetic biology is to emulate 
naturally occurring motifs. Here, available set of the first design principles is used 
and extended, linking peptide structure and function. Additional manipulations to 
the amino acid sequence are based on further or refined rules, provided by through 
intuitive and empirical designs as well as computational analyses. Targeting specific 
function determines the nature and structure of a given design, but often it is the 
delineation of closely related functions that require subtle tuning in the sequence, 
backbone or side chains. For example, generic peptide sequences can be designed 
to provide cell penetrating and gene delivery properties, thus promoting the uptake 
and intracellular release of DNA and enabling expression of target proteins,32 and 
can be tailored for differential membrane binding enabling related functions of 
endosomal release and antimicrobial responses.33 
Endogenous antimicrobial peptides are often used as biomarkers in 
peptidomics (wound healing monitoring, inflammatory responses). They present an 
evolutionarily conserved class of the host defence effector molecules. Apart from 
being promising candidates for next-generation antimicrobials, in the light of 
emerging antimicrobial resistance, the peptides are extensively being used as 
structural templates for mechanistic and structural studies at the cellular and 
systems level, providing convenient interfaces between systems biology and 
peptidome analysis. Recently, high resolution imaging techniques are being 
employed to address fundamental questions of peptide interactions with their 
targets in real time and with nanoscale precision. De novo design and nanoscale 
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imaging, used in combination, were shown to reveal mechanisms that could not be 
understood using more traditional approaches in structural biology including NMR 
and crystallography.33 Somewhat reverse to this approach is the use of de novo 
engineered peptides as tools for targeting native antimicrobial peptides. These 
peptides cannot bind to membrane surfaces, microbial or mammalian, and are 
anionic in contrast to cationic antimicrobial peptides, which allows them to bundle 
with the antimicrobial counterparts into functionally inert coiled-coil 
heterooligomers (Figure 1).34 In this format, the peptides act as antagonists of 
antimicrobial peptides or anti-antimicrobial peptides and can be used as means for 
capturing endogenous antimicrobial biomarkers.  
 
 
 
Figure 1. Examplar engineered peptide, portraying two scenarios of antimicrobial peptide action:  
an antimicrobial peptide binds to microbial membranes and forms membrane-disrupting helical 
structures (left) or when challenged by an anti-antimicrobial peptide it forms a biologically inert 
helical complex (right). Adapted with permission from Rakowska, et al., in Amino Acids, Peptides 
and Proteins; Eds. RSC Publishing, 2013, 38, 172-202.
35
 Copyright © 2013 Royal Society of 
Chemistry. 
 
By designing and using such systems one can expand proteome analysis. 
The elucidation of antimicrobial resistance at the level of specific peptide-lipid 
interactions with correlative studies of resistant and wild-type bacterial membranes 
in situ, in vitro and potentially in vivo can be enabled. Importantly, peptidome 
analysis takes a proactive role in the search of resistance mechanisms from the 
bottom up, from relatively simple scenarios, such as the expression of neutralising 
sequences, to more complex routes leading to membrane modifications or 
re-building.34  
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1.4. Peptidomics 
As described above, peptides play central role in physiological processes. They can 
serve as excellent biomarkers and can be also used as templates in chemical biology 
for construction of molecular probes. Therefore, there is a need for the continuous 
development of technologies, which would enable comprehensive analyses of the 
entire peptidomes of cells, tissues and, in principle, whole organisms. Peptidomics – 
the area of comprehensive studies of peptides, is strongly related to proteomics, 
where protein analyses mostly rely on obtaining protein-derived peptide fragments, 
their analysis and sequencing.36, 37   
Peptidomics and proteomics share many of the scientific objectives, 
technologies and techniques. Nevertheless, there are several key differences 
between these fields. These differences result from the size of peptides, origin, 
specific modifications and activity. Therefore, the same methods, which are well 
established to “mine” the proteome, unless altered to the analysis of naturally 
occurring peptides, often cannot be easily applied for peptidomes. For example, 
most of proteomic studies use proteolytic enzymes such as trypsin to obtain well 
defined fragments that can be subsequently analysed by mass spectrometry (MS). 
In contrast, in peptidomic studies digestive enzymes are scarcely employed as this is 
the native form of the peptides that is of scientific interest and the size already 
allows the use of mass spectrometry. Sample preparation for peptidomic studies 
can be more straightforward without proteolysis; however, data analysis can be 
more difficult in this case, especially for the analysis of larger peptides and those 
with multiple post translational modifications or those that contain unusual amino 
acids. This can influence not only the sensitivity of MS experiments but also affect 
prediction methods and the understanding of peptide fragmentation patterns in 
mass spectra.  
1.4.1 Peptidomic processing 
The analysis of peptides in complex biological samples can prove challenging.  One 
of the difficulties in analysing complex media comes from the wide dynamic 
concentration ranges of various components in biological matrices. Very often some 
of the most important analytes are present at very low levels and masked by high 
abundance biomolecules.38-40  
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A combination of several techniques is almost always required to enable 
analyses of obscured biomolecules. Several strategies, forming multi-step 
workflows, have been developed and combined together in order to overcome 
biological sample complexity. An example of such a workflow is given in Figure 2. It 
shows major techniques used in peptidomic sample processing.  It starts with 
a sample depletion to remove most abundant proteins, such as albumin and 
immunoglobulins, which can interfere with the detection of less abundant 
molecules. This is followed by sample fractionation and purification using 
chromatographic separations to further reduce the complexity of the sample.  
Peptide detection and identification is finally carried out by mass spectrometry, 
supported by computational methods. 
 
 
Figure 2. Flowchart of a typical peptidomic process: Tissue sample, after homogenisation and 
initial clean-up, is processed by nano-LC MS. Mass spectra are acquired continuously during the LC 
run and mass spectrometer software uses the MS spectrum to decide on peak selection for 
fragmentation using collision induced dissociation (CID) and MS/MS analysis. The obtained 
fragmentation spectra are converted to peak lists which are then used for query of a database. 
Reprinted from Baggerman, et al., J Chromatogr  B, 2004
41
 with permission from Elsevier. 
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1.4.2 Liquid chromatography – mass spectrometry interfaces 
Mass spectrometric techniques are well suited for peptidomic studies. They allow 
obtaining accurate and reliable information, often in a high-throughput manner. 
The techniques enable the detection of low-molecular-weight peptides at very low 
concentrations with adequate resolution and sensitivity which makes them a useful 
tool for peptidome profiling. 
MS techniques can be applied to almost any kind of biomolecules including 
proteins, lipids, nucleotides and amino acids. However, to be sufficiently sensitive, 
they require relatively pure samples in certain buffer / solvent compositions. 
Therefore, multidimensional strategies are nearly always essential in the analysis of 
biological samples.  
Sample clean-up presents, usually, the first step in multidimensional 
peptidomic analyses. Size-based separations are occasionally employed for 
the separation of desirable peptide biomarkers or biomarker series. There are 
reports on successful approaches based on methods such as IEF, GE or even SEC.42-
45 However, they are not exclusive of drawbacks such as the amount of analyte 
necessary, usually relatively high for successful separations. Also, the nature of this 
kind of separations makes them efficient mainly for higher molecular weight 
components (>5 kDa).46 Therefore, peptidome analyses are based, most often, on 
gel-free approaches. Additionally, there are many traditional procedures, which can 
be used, resulting in peptide-rich extracts, such as ultrafiltration,47-49 the use of 
trifluoroacetic acid50 and organic solvent extraction.51, 52 The choice of a particular 
purification protocol needs to be carefully thought through and tailored to 
the specific target molecule.53  
After initial extraction and enrichment, peptide pools are next introduced to 
liquid chromatography separations. A multidimensional chromatographic set-up is 
often employed. Ion exchange chromatography (IEX) presents a conventional 
method, which enables, in the first instance, separations based on pI values. 
Nevertheless, anything from immunoaffinity to chemical separations can be 
successfully applied, i.e. MS-preceding SEC analysis,43 2D-Hilic MS,54 or 
two-dimensional 2D-HPLC run at basic pH (first dimension) followed by acidic pH 
(second dimension).55 
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Any salt-containing buffers used to pre-fractionate complex samples can 
hamper mass spectrometric detection. Therefore, the most common 
chromatographic step, directly preceding MS analysis, is a reversed-phased liquid 
chromatography (RP-LC). RP-LC is a MS-compatible technique as it allows setting 
elution gradients with the use of organic solvents such as acetonitrile with addition 
of proton donors i.e. trifluoroacetic acid or formic acid. These kinds of solvents are 
volatile and often promote analyte ionisation, enhancing MS sensitivity. 
For the identification of peptides, individual RP-LC fractions are introduced to 
mass spectrometric analyses. Soft ionisation detection methods, such as MALDI and 
ESI MS, which rely on the precise measurement of the peptide mass, are preferred. 
Tandem mass spectrometry, i.e. nESI-TOF-MS/MS or MALDI-TOF/TOF-MS, can 
provide fragment spectra of the chosen parent ion, which is used to identify 
a corresponding peptide sequence.  
1.4.3 MS-based quantification 
Mass spectrometry is an essential tool in peptidomics for detection, identification 
and characterisation. It also presents the main tool for quantitative peptide 
analyses. Quantitative approaches can be divided into two categories, those 
that provide absolute and relative quantification and those that are label-based and 
label-free (Figure 3). 56, 57 
The strategies of relative quantification58-60 are based on the comparison 
between the levels of individual peptides in a sample with those of an identical 
sample, in which the same compounds have been modified. In a typical experiment, 
peptides from two experimental samples are isotopically labelled, totally or at 
specific amino acid positions. Those two samples that contain the equal amounts of 
peptides are combined and can be analysed by LC-MS. Properties of the individual, 
differently labelled species coming from both samples remain identical, and hence 
they co-elute and are detected by MS at the same time. The intensities of 
corresponding heavy and light peptide ions are then compared for concentration 
differences. 
Label-based methods     
There are several methods enabling the use of peptide labels. They include: 
 Metabolic labelling, the most common version of which may be stable-isotope 
labelling in cell culture (SILAC) (Figure 3(A)). This method involves in-vivo 
  
 
34 
 
incorporation, during cell growth and division, of a stable isotope labelled amino 
acid into the proteome/peptidome of the cells, which are added to cell culture 
media.61-63 To carry out the relative quantification control cells grown in regular 
media are used. The main advantage of this method lies in its relatively simple 
protocol and the minimal manipulation of the probed systems. Nevertheless, this 
method is almost only appropriate to cell samples and may not be applicable to 
those that are sensitive towards changes in culture medium composition. 
 Chemical labelling (Figure 3(B)) can be applied to samples that cannot be 
processed with metabolic labelling such as tissues or biological fluids, or when short 
experimental time is necessary. Many strategies involving chemical or enzymatic 
stable isotopic labelling have been developed, such as enzymatic labelling with 18O, 
where tryptic digest is performed in water containing 18O and another in water with 
16O. The mechanism of trypsin action incorporates the oxygen atoms at 
the C-termini of freshly digested peptides.64, 65 This method however may not be 
suitable to study endogenous peptides or when the trypsin use is not appropriate. 
Stable isotope dimethylation is another example of chemical labelling, which 
involves the labelling of primary amines with deuterated methyl groups by 
formaldehyde in deuterated water.66 ICAT (Isotope Coded Affinity Tag) is the most 
utilised of the cysteine tagging methods.67, 68 This strategy requires a label 
composed of three parts: an isotopically labelled (deuterated) linker, biotin group 
and a cysteine reactant. Once peptides are labelled, they are subjected to column 
chromatography with immobilised avidin or streptavidin. Then biotin enables 
separation and enrichment and analysis of cysteine-containing peptides. This 
method is applicable to these species only. 
 Isobaric tagging with reagents such as iTRAQ (Figure 3(C)).69-71 It requires 
analysis with tandem mass spectrometry because isobaric tags have identical 
masses and chemical properties. Therefore, there is no distinction during the LC and 
MS runs. During MS/MS experiment, in the collision cell when the peptide parent 
ion collides with gas molecules, the tags are cleaved from the peptides. The peptide 
ions are sequenced and the tags are quantified. This allows the simultaneous 
determination of both the identity of the analytes and their relative abundance. 
Because the MS/MS is set up only for the tag detection unlabelled peptides are not 
quantified. 
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Label-free methods     
Label-free quantification methods are used for both relative and absolute 
quantification.59, 72, 73 These methods are also well suited for high-throughput 
screening and biomarker discovery experiments. They do not require control or 
differently labelled samples. Samples are prepared independently and analysed by 
LC-MS or LC-MS/MS. Nevertheless, the lack of controls imposes planned carefully, 
controlled and reproducible processes to avoid experimental variations.   
In instances where ion signal intensity correlates with peptide concentration, 
as for example in electrospray ionisation experiments, the quantification of 
peptides can be performed taking into account ion intensity. These quantitative 
approaches are exclusively based on LC-MS and the relative levels of peptides 
between analysed samples can be directly estimated from the peak intensities 
(Figure 3 (E)).   
Another type of label-free relative quantification is executed using spectral 
counts. This method requires tandem-MS set up and involves the comparison of 
the sum of MS/MS spectra originating from a peptide of interest across multiple 
samples, which correlates with the analyte abundance.  
 
Absolute quantification74-76 is possible by a label-free approach. This approach 
requires the preparation and incorporation of internal standards – isotopically 
labelled, heavy analogues of the probed peptide, which are spiked at known 
concentrations into the experimental sample (Figure 3(D)). The spiked sample is 
next subjected to processing by LC-MS. Though having different masses, chemically 
the peptides are identical. Therefore, they co-elute and are analysed by MS 
simultaneously. The abundance of the target peptide ion is compared to 
the abundance of its isotopically labelled analogue in the analysed sample and 
the quantification is performed with the use of a prior-built standard curve. A neat 
example is an isotope dilution approach for the quantification of cellular uptake of 
cell penetration peptides (CPPs) as described by Burlina, et al.77 This method uses 
magnetic beads for peptide harvesting followed by direct peptide analysis by MALDI 
MS. Quantification is achieved using a deuterated analogue of the analysed CPP as 
a standard (Figure 4).  
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Figure 3. Overview of quantification workflows. The points, at which peptides are labelled, or at 
which isotopically labelled analogues are used, are indicated by colours blue and red (heavy). 
Metabolic labelling takes place in vivo. Reprinted with permission from Rakowska, et al., in Amino 
Acids, Peptides and Proteins; Eds. RSC Publishing, 2013, 38, 172-202.
35
 Copyright © 2013 Royal 
Society of Chemistry.  
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Figure 4. MALDI mass spectra presenting the results of isotope dilution-based quantification. The 
first isotope of the signals is identified for both [1H]peptide (m/z = 2,100.2) and [2H]peptide 
including the component with eight deuteriums (m/z = 2,108.2) and the non-completely 
deuterated components (m/z = 2,105.2, 2,106.2 and 2,107.2). Signals including all isotopes as 
delimited in the figure are taken into account in the quantification. Adapted with permission from 
Burlina, et al., Nat Protoc, 2006.
77
 Copyright © 2006 Nature Publishing Group.   
 
Absolute peptide quantification would be an ideal outcome. However, the relative 
quantification approaches are used more often. There are several reasons for that. 
This method is mainly limited to analysis of one analyte at a time and does not allow 
monitoring changes in abundance of several compounds in one sample 
simultaneously.  Often time-consuming assay development has to be carried out for 
any peptide of interest and fabrication of isotopically labelled reference molecules 
can be often expensive due to costly reagents. Nevertheless, the choice of 
quantification method is dictated by the molecule in question and the type of 
biological samples to be analysed. Where the analyte to be quantified is well 
defined, such as the example of the detection of a single peptide biomarker, or 
when a defined marker is introduced to the system (as described further), methods 
based on isotopic labelling seem to be most advantageous. Firstly, the application of 
absolute quantification can be performed. But most importantly, when probing 
biological samples in the search for real answers, it is often crucial to retain the 
physico-chemical properties of both the analyte and the analysed samples. Isotopic 
labelling, regardless of the choice of the set up (label-free versus label-based), when 
properly designed and executed, should have no influence and should not invoke 
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any alterations to the natural behaviour of the analysed system, as is often the case 
with other tagging ligands.  
1.5. Systems biology 
Together with genome sequencing and the emergence of high-throughput 
analytical technologies an area of systems biology has emerged. This inter-
disciplinary field seeks to explain biological processes using frameworks of complex 
interactions describing biochemical and cellular modules within an individual cell or 
an organism. ‘Omics’ technologies, which encompass genomics, transcriptomics, 
proteomics, metabolomics, lipidomics, glycomics and many others, existing and 
emerging, make it possible to collect and analyse comprehensive data sets on 
intricate biological processes.  
Some see peptidomics as a complementary branch of proteomics. As 
aforementioned, many similarities between these two fields exist. However, it is 
best to see peptidomics as a discipline that complements proteomics by creating 
a bridge between proteomics through degradomics to metabolomics, even though 
endogenous peptides are not necessarily associated with proteome degradation. 
For other related “-omics” approaches, for example peptidoglycans and 
lipopeptides, which can fall under glycomics and lipidomics, respectively, 
the emphasis is equally split between the variabilities of glycans and lipids and 
the peptide sequence constitution. It is therefore common to relate different “-
omics” capabilities with appropriate weighing of information obtained by a specific 
discipline.  
There are obvious overlaps as well as links between different complex 
“-omics” disciplines. One example could be the combination of lipidomics studies 
with peptidomics, addressing molecular processes underlying the action of 
membrane-active peptides. Lipidomics data, concerned with the composition of 
biological membranes, aid understanding of how the peptides distinguish between 
mammalian and bacterial cells and how the lipid spectrum and membrane 
architecture influence the primary role of those peptides.  
Systems biology addresses the links between “-omics” disciplines. It integrates 
complex data from multiple experimental sources. Starting from the understanding 
of the genetic information through the variations in the code, gene expression, 
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nucleic acid-protein binding, to molecule-molecule interactions, the networks of 
relations and dependence can be built, which would enable a deeper understanding 
of the underlying molecular biology of a given physiological state or process.78, 79 
 
 
 
Figure 5. Schematic representation of a model of the “-omics” technologies landscape including 
examples of corresponding analytical subjects, and applied methods; DNA (genomics) undergoes 
transcription to mRNA (transcriptomics), which is next and translated into protein (proteomics). 
Proteins assist catalytic reactions resulting in metabolites (metabolomics), glycoproteins and 
carbohydrates (glycomics), and various lipids (lipidomics).  Reprinted with permission from Wu et 
al., J Dent Res, 2011.
78
 Copyright © 2011 Int. & American Associations for Dental Research. 
1.6. Nanotechnology-enabled tools  
With the growing demand for high-throughput methods, applications based on 
nanotechnology have a great exploitation potential and are resulting in 
a development of new technologies in different sectors of life science, including 
the diagnostic and peptidomic / proteomics fields.  
Nanomaterials offer efficient agents to overcome persistent deficiencies of 
conventional methods in, for example molecular diagnostics and medical imaging. 
The interest for nanomaterial use and further development has been steady over 
the last two decades and has just begun its expansion into other areas including 
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peptidomics and proteomics. Clearly, the variety and repertoire of nanomaterials 
that can facilitate peptide / protein biomarker detection, to the point of clinical 
implementation, is not limited to one single class. Examples may include nanoscale 
particles, wires and tubes and their nano arrays. Primary attention here is given to 
the ability of a specific nanotechnology to refine or extend detection limits, which 
would otherwise require complex and cost-ineffective optic or immuno-based 
technologies. In this respect, the chemistry and morphology of a particular material 
play an auxiliary role and are important from the perspective of a specific 
experimental set-up. For example, carbon nanotube arrays assembled on the tips of 
molecular-imprinting sensors used in combination with electrochemical impedance 
spectroscopy can detect proteins with subpicogram per litre sensitivity,80 whilst 
nanowire gated transistors or label-free nanomechanical cantilever sensors can be 
constructed for the detection of multiple and real-time binding events, which can 
enable multiplex biomarker detections.81, 82 
1.6.1 Nanoparticles 
Among the nanoscale materials the use of nanoparticulate systems appears to be 
predominant. Because of their universal and unique physico-chemical properties, 
nanoparticles are most attractive candidates for proteomics.83-86 Specifically, their 
large surface-to-volume ratios ensure much faster reaction rates when compared to 
those of polymeric, colloidal, inorganic bulk or monolithic materials. The porosity of 
porous particles can be controlled to substantially enhance adsorption, and their 
surfaces can be tailored by chemical modifications to allow the fabrication of 
selective adsorbents.87-90 These properties combined facilitate the capture and 
detection of specific analytes from biological fluids at subnanomolar 
concentrations. 
Two main strategies are being followed for the development of 
nanoparticle-based analytical probes.91 The first strategy relies on surface-tailored 
nanoparticles aiming at simplifying complex samples prior to analysis (Figure 6 (a)). 
This can be done with the help of nanoparticles coated with either porous materials 
or ionic functional groups enabling size- and charge-dependent fractionation of 
multi-component samples, respectively.91-93 The nanoparticle fraction, carrying 
the captured molecules, is separated from the depleted fraction of the sample. In 
this format, either fraction may contain the target analytes, which are easier to 
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identify. However, isolating molecules of interest from media tends to be favoured, 
particularly given that the captured analytes can be directly eluted from 
the nanoparticles for subsequent analysis by mass spectrometry or electrophoresis. 
Alternatively, nanoparticles can be analysed directly and in some instances, for 
example in laser desorption ionisation mass spectrometry (LDI MS) methods, 
the direct measurement of nanoparticles can improve the signal-to-noise ratios.94-97 
The second strategy (Figure 6 (b)) encompasses the covalent conjugation 
affinity tags to nanoparticles in order to selectively target individual analytes. 
Tagged nanoparticles have shown promise in various applications including 
molecular therapy, diagnostics and catalysis. Owing to their intrinsic polyvalency 
and relative uniformity in size and morphology these nanoparticles can provide a 
variety of functions ranging from direct traversal across biological membranes to 
multiple targeting and amplified sequestration.98-101  
 
 
Figure 6. Cartoon portraying biomarker harvesting from a complex sample by surface-tailored (a) 
and affinity tagged (b) nanoparticles. Reprinted with permission from Rakowska et al., Biomarkers 
in Medicine, 2011.
102
 Copyright © 2011 Future Medicine Ltd. 
 
The use of nanoparticles imposes certain drawbacks. Most nanoparticles used for 
analyte capture or detection are polymeric or metallic colloids whose surfaces may 
adsorb plasma proteins leading to aggregation or undesired phagocytosis, if 
performed in tissues or in vivo. Surface modifications by charged or lipidic moieties 
can be sufficient to circumvent these drawbacks. However, the challenge remains 
and in some cases there are requirements for oriented immobilisation of 
biomolecules in order to preserve and sustain their folding-mediated function. 
Nevertheless, recent successes in the development and application of nanoparticle-
based platforms are notable and some of them highlighted below. 
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1.6.2 Nanoparticles for biomarker diagnostics 
An excellent example to introduce the utility of nanoparticle-based technology is 
a platform developed by Liotta and co-workers.103 The technology uses “smart” 
nanoparticles – hydrogel particles engineered to selectively harvest classes of 
biomolecules from biological fluids such as plasma and urine.103-105 Highly porous 
particles constructed from poly(N-isopropylacrylamide) were shown to serve as 
molecular sieves discriminating sample components according to their size. 
The porosity of the particles was tuned to capture molecules with sizes < 20 kDa. 
Peptides and small proteins in this molecular weight range are not accessible in 
sufficient yields by electrophoretic or chromatographic methods. Such a cut-off in 
pore sizes corresponds to a certain degree of cross-linking within the particles, 
which can be empirically controlled. Hydrogel nanoparticles proved to exclude high 
abundance molecules (i.e. albumin) and to sequester proteins of smaller sizes. 
Although efficient and consistent with the design, poly(N-isopropylacrylamide) 
particles cannot guarantee the full depletion of sample solutions from target 
analyte because the analyte concentrations in the particles remain in equilibrium 
with those in the bulk solution. To address this, the particles were modified to 
incorporate affinity baits to prevent the escape of captured molecules back into 
solution (Figure 7).103 By incorporating anionic tags it was possible to select cationic 
species, while enhancing their uptake leading to significantly higher concentrations 
in the particles. Thus, the system is particularly appealing since it can be tailored for 
specific requirements simply by varying its chemistry and the degree of 
cross-linking, and it can enable encapsulation and enrichment of low molecular 
weight fractions from complex samples and their simultaneous enzymatic 
protection against degradation during subsequent sample treatments. The platform 
has been validated for harvesting human growth hormone from urine samples104 
and platelet derived growth factor from serum.105  
 
  
 
43 
 
 
Figure 7. Concept of size- and charge-based biomarker harvesting by engineered gel nanoparticles. 
Only the passage of positively charged and low molecular weight molecules is endorsed. Reprinted 
with permission from Luchini, et al., Nano Letters, 2007.
103
 Copyright © 2008 American Chemical 
Society. 
 
Most recently, a different protocol for using hydrogel nanoparticles was proposed 
by Cerasoli, Rakowska et al.106 The authors proposed direct mass-spectrometric 
analysis of analyte-loaded gel particles without eluting the captured molecules from 
the nanoparticles. The design of the MIS-MALDI (Microgel Selected MALDI) platform 
was set off from two main criteria: (1) to afford low detection levels of specific 
analytes in multi-component media, a physicochemical means for harvesting and 
enrichment had to be introduced, and (2) the chosen means had to allow on-probe 
analysis of captured analytes at standard MS conditions. Gel particles were able to 
extract target proteins, such as human growth hormone, from complex media 
according to their size (<30 kDa) and isoelectric points (protein pI <6.5).  
 
 
 
Figure 8. Diagram of MiS-MALDI. Microgel particles are dispersed in a multi-component protein 
solution to harvest protein biomarkers, which are selected by their size and charge (pI). The loaded 
particles are isolated and analysed by MALDI-ToF MS. Reprinted from Cerasoli, Rakowska, et al.,  
Mol Biosyst, 2010
106
 with permission from the Royal Society of Chemistry. 
 
  
 
44 
 
These types of approaches, allowing on-probe detection offer considerable 
throughput in areas such as biomarker discovery. However, the strategies work well 
only for the ‘‘class specific’’ selection of biomarkers. Nevertheless, they could be 
taken further, as the chemical composition of the gel particles can readily be 
tailored to meet more selective discrimination of different biomarker types. For 
example, nanoscale systems for a specific peptide binding can be designed using 
functionalised polymer particles possessing high affinity for biomacromolecular 
toxins (melittins) with simultaneous neutralisation of their toxic effects. 
Co-polymeric nanoparticles constructed from different functional monomers were 
shown to be able to capture and neutralise the toxicity of melittin even in a complex 
biological milieu (Figure 7). 107 
 
 
Figure 9. Melittin–NP interaction: Contributions of hydrophobic (light arrow) and electrostatic 
(dark arrow) interactions between melittin and NPs 7 (a), 6 (b), 2 (c), and 5 (d). Contributions of 
polymer density to interactions between melittin and NPs 9 (e) and 10 (f). Reprinted with 
permission from Hoshino, et al., Small, 2009.
107
 Copyright © 2009 Wiley-VCH Verlag GmbH & Co. 
KGa, Weinheim.  
 
1.6.3 Multimodal nanoprobes 
There is little doubt that the number of similar to the described above 
technologies will be growing. However, it would be of considerable advantage to 
develop tools, which would carry more specialised functions. One example for 
the use of such technologies could be the identification of disease specific 
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biomarkers. Arguably, major progress has been made in the area of cancer. Two 
main directions can be identified in the application of nanoparticle-aided assays for 
cancer diagnostics: 1) the development of tumour-targeting functionalised 
nanoparticles and 2) nanoparticle-based sensors.   
Metallic nanoparticles are an attractive alternative to the mainly “class 
specific” polymeric particles in the development of highly selective targeting tools. 
They present a diverse class of materials with size that can be tuned and surface 
chemistries, which allow their modifications and functionalisation with multiple 
ligands. In addition, the surface plasmon in metallic particles provides them with 
remarkable optical properties what yields a wide range of applications in 
the diagnostics and bio-medical fields.  
Multi-modal nanoparticles or multi-modal nanoprobes are nanoparticles 
functionalised with multiple molecular motifs or tags, each carrying a specific 
function. Main uses for these particles include tumour targeting and 
contrast-enhanced imaging. For instance, nanoparticles containing strong contrast 
agents such as iodinated and gadolinium-based reagents can be used in magnetic 
resonance imaging or angiography.108-110 Because contrast agents may be 
associated with cytotoxicity, their encapsulation is sought to minimise cytotoxic 
effects. In many instances, coating the particles with inert polymers or lipids proved 
to be equally efficient, and provided stable and biocompatible probes. 
The nanoparticle surfaces can then be modified with antimetabolites, integrin 
antagonists or micronutrients to target or accumulate at cancer sites. 
A representative example is shown in Figure 10. 
The probes of this type can generate strong MRI signals at lower 
concentrations of contrast agents, efficiently compromise uptake into 
non-malignant cells, and exhibit increased circulation time and bioavailability. 
Similar probes can be made based on magnetic nanoparticles, which can provide 
dynamic contrast agents. When activated by an externally applied magnetic field, 
these probes can modulate the optical scattering properties of local tissue (tumour) 
microenvironments allowing local changes monitoring with a displacement 
sensitivity of a few tens of nanometres.98, 109 
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Figure 10. Schematic drawing of a multi-modal nanoparticle for tumour targeting and imaging. 
Reprinted with permission from Rowe, et al., Biomacromolecules, 2009.
111
 Copyright ©2009 
American Chemical Society. 
 
Nanoparticle-based sensors can provide increased specificity in tumour 
detection. Metal nanoparticles conjugated to antibodies or ligands that are specific 
to cellular receptors such as integrins, integrin-associated and growth-factor 
receptors can discriminatively detect malignant cells, which shed the receptors in 
soluble forms in amounts exceeding those in normal or dysplastic cells.112-114 Given 
that this directly correlates with enhanced invasiveness of malignant cells, 
nanoparticles with immobilised receptor-recognising moieties are deemed to be 
efficient tumour-targeting agents. Indeed, engineered nanoparticle sensors display 
higher (up to an order of magnitude) affinities to cancerous cells than to normal 
cells thereby making the detection of tumours possible merely by optical 
microscopy or surface plasmon resonance.115, 116 If exposed to laser or thermal 
treatments (i.e. continuous argon ion lasers or alternating magnetic field) 
the nanoprobes accumulated in tumour sites require only half the energy needed to 
affect normal cells to destroy cancer cells.115, 116 The large surface areas of 
nanoparticles can be exploited for finding optimal agonist-antagonist affinities 
using, for example, large libraries of receptor-specific peptide ligands diversifying 
thus both the choice and modalities of nanoparticulate sensors.117, 118 
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1.7. Conclusions  
The increasing knowledge of peptidome content and analysis, together with 
advances in associated techniques, physicochemical strategies, bioinformatics and 
nanotechnology provides an important insight into the nature and role of peptides 
and peptide biomarkers in complex biological systems. It can also lead to 
the creation of new peptide-based technologies with a reach beyond traditional 
peptidomics applications. New possibilities exist for efficient peptidomic 
technologies. However, primary attention is still given to the discovery of new 
predictive peptide biomarker patterns and analyses of endogenous peptides.  
Understanding peptidomes and, in particular, peptide-mediated interactions 
underlying their complexity and diversity, is critical for the development of more 
reliable and robust analytical platforms. The use of engineered synthetic peptides is 
still of lesser emphasis in the literature, primarily due to molecular diagnostics 
approaches and nanoscale technologies that are developed in parallel and inter-
relate with peptidomics at the point of mutual applications – the tendency which 
can be anticipated to develop further. At the same time, there is little doubt, that 
being once of a specialist chemistry area, the principles of nanotechnology are now 
being adapted to generate powerful tools aiding various areas of research and 
medicine. Of immediate relevance in this respect are those approaches that 
concentrate on the platforms, which carry multiple functions such as multi-modal 
nanoprobes. The implementation of nanoscale strategies and developments of 
nano-enabled technologies hold promise for “smarter” tools with various areas of 
application in life sciences, diagnostics and medicine. 
1.8. Aim of the study   
Mimicking peptides or producing chemically modified peptide structures with 
certain properties can be crucial. It could aid the creation of new, nanoparticle-
based diagnostic methods as well as targeted drug and gene delivery agents. 
The goal of the project is to study specialist cellular targeting, using rationally 
designed membrane-active peptides as ligands for a generic nanoprobe 
functionalisation. The project serves a long-term view of developing nanoscale 
peptide probes for applications in cell biology. The development of such probes 
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requires detailed understanding of functions and properties of their each 
component. 
 
Firstly, de novo designed antimicrobial (AMPs) and cell penetrating (CPPs) peptides 
are investigated as model systems for differential cellular membrane interactions.  
   Antimicrobial peptides are postulated to disrupt microbial phospholipid 
membranes. The principal molecular model of their action is based on 
the formation of stable or transient pores although the direct observation of 
the fundamental processes is lacking. This project gives an insight to this process by 
using a novel approach of nanoscale imaging. The imaging of peptide interactions 
with microbial membranes, in the form of supported lipid bilayers, is conducted 
with two surface analysis techniques: atomic force microscopy (AFM) and 
high-resolution secondary ion mass spectrometry (NanoSIMS). This way 
topographical information obtained with AFM is complemented with chemical 
details provided by NanoSIMS. 
Cell penetrating peptides can efficiently traverse mammalian cell membranes 
and deliver various cargo materials. Therefore, CPPs could be used as robust and 
specific delivery agents or employed create functionalised molecular probes for 
intracellular targeting. However, the functional efficiency of cargo often depends on 
the completeness of intracellular peptide uptake. Existing approaches rely on 
the use of radioactive and fluorescent labels or tags which allow colorimetric, 
fluorescent or spectrometric detection. Controversies remain regarding discordant 
results in different studies and the need for artificial labelling, which continue 
questioning the general applicability of these methods. Therefore, the 
quantification remains largely unconvincing. Peptidomic processing is implemented 
in this project to study the uptake of the model CPP. Two-dimensional 
chromatography followed by isotope dilution MADLI mass spectrometry is 
performed for the lysates of human dermal fibroblasts transfected with the CPP. 
The method offers a generic label- and tag-free approach for intracellular 
quantification, which can be used as a correlative measure for fluorescence-based 
imaging methods. 
 
Secondly, the development of generic nanoprobes, functionalised with the studied 
synthetic peptides is carried out (Figure 11). 
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Nanoparticles can underpin creation of very specific and sensitive platforms. 
They present a diverse class of nanoscale materials. Their surfaces can be modified 
to create highly selective adsorbing species or to incorporate desirable molecules. 
However, issues arise from the reactive nature of nanoparticles. Many different 
molecules can easily react with particle surfaces, which present a particular 
challenge in terms of their application to complex biological systems. Therefore, 
before particles can be used for analysis in such samples their surfaces should be 
passivated to prevent those interactions. 
To overcome non-specific physisorption, metallic nanoparticles are firstly 
coated with surface-passivation moieties (lipid bilayers and polyethylene glycol), to 
which designed model peptides of cell penetrating properties are next conjugated. 
Nanoparticles allow their direct imaging (without the need of additional tags or 
staining) by transmission electron microscopy. Therefore, the ability of the created 
probes to interact with mammalian cells is investigated by this technique. 
 
 
 
Figure 11. Drawing of a functionalised nanoparticle. 
 
 
This project offers a basis for the fabrication of nanoprobes, which can be readily 
conjugated with peptidic moieties of desired properties and activities. Summary of 
the project is represented in Figure 12. 
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Figure 12. Graphical summary of the project subjects. 
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  CHAPTER 2
MODEL PEPTIDES FOR CELLULAR TARGETING – ELUCIDATION 
OF MECHANISM OF ACTION 
 
 
 
 
2.1. Summary 
De novo designed, membrane-active peptides are investigated to probe specialist, 
selective cellular targeting. The ultimate aim is to use the peptides as model ligands 
in functionalisation of nanoparticle-based probes for extracellular binding and 
intracellular transport.  
This chapter focuses on a novel approach to study the action mechanism of 
antimicrobial peptides. A combination of surface analysis techniques (AFM and 
NanoSIMS) is used to probe changes in supported lipid bilayers as a result of 
interactions with the designed peptides. Differential membrane targeting (bacterial 
versus mammalian) is chosen as model milieu. The work resulted in two 
publications: 1) ‘Nanoscale imaging reveals laterally expanding antimicrobial 
pores in lipid bilayers’, P D Rakowska, H Jiang, S Ray, et al.; PNAS, 2013, 110, 
8918-8923; and 2) ‘Stable isotope imaging of biological samples with high 
resolution secondary ion mass spectrometry and complementary techniques’, 
H Jiang, E Favaro, C N Coulbourne, P D Rakowska, et.al.; Methods, 2014, 2014, 68 
  
 
52 
 
(2), 317-324. Full versions of the articles can be found in ‘Publications from the 
project’ section of this thesis. 
2.2. Introduction  
2.2.1 Antimicrobial peptides as model system  
Antimicrobial peptides (AMPs) are endogenous effector molecules of the innate 
immune system of all multicellular organisms. Due to their high surface activity and 
remarkable biological properties these peptides are of increasing interest. Most of 
AMPs are membrane-active. Their amino acid composition, amphipathicity and size 
allow them to attach to and insert into membrane lipid bilayers or enable them to 
penetrate the cells and to bind to intracellular targets, crucial to cell living. They are 
attracting growing attention as potential drug candidates and efficient anti-infective 
agents as well as components in diagnostic probes and drug delivery systems. 
However, before they can be used as such, and on an industrial scale, 
a considerable effort has to be put to firstly understand the basis of their biological 
activity and mechanisms of action. 
Bacterial membranes differ from mammalian membranes in lipid composition 
and architecture. Membrane-active peptides are able to interact with both kinds. 
However, a particular effect of the interaction is based on the membrane type. 
Interactions with microbial membranes are non-selective and aimed at 
the membrane disruption, leading to bacterial lysis. The understanding of how 
these peptides distinguish between bacterial and mammalian cell membranes, 
based on the membrane lipid composition, allows for the design of archetypal 
peptides, which can aid in the elucidation of the molecular mode of action of 
antimicrobial peptides and can underpin the future exploitation of these peptides. 
By further manipulating their properties towards selectivity to particular microbial 
species, classes of novel antibiotics or specific probes could be devised.  
2.2.2 Poration 
AMPs are designed to kill microbial cells, not necessarily specifically, but rapidly. 
Few of the naturally occurring AMPs have been studied to expose the molecular 
mechanism of action and several models have been proposed including barrel-stave 
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pore, toroidal pore and carpet models ().119 However, the direct observation of 
the fundamental processes is needed.  
 
 
 
Figure 13. Current models of the action mechanism of membrane-active antimicrobial peptides:  
(A) toroidal pore model, (B) barrel-stave model, (C) carpet model. Adapted with modification from 
Brogden, Nat Rev Micro, 2005
119
 with permission of Nature Publishing Group. 
 
The prevailing molecular model for AMP action is based on the formation of 
stable or transient pores. In lipid vesicles120, 121 and supported bilayers,122 kinetic 
studies imply the formation of transient pores,123 suggesting that antimicrobial 
peptides may expand through the monolayers of the lipid bilayers.120-122, 124 Much 
research has also focused on small and stabilised pores.120, 125-127 Growth arrest and 
uniform sizes of pores conform to the functional and structural rationale of 
specialised transmembrane proteins128, 129 but may not be consistent with that of 
antimicrobial peptides. Heterogeneity in pore formation for AMPs may derive from 
the fact that, unlike the case of membrane proteins, there are no a priori 
topological constraints on assembled structures that the peptides must adopt in 
bilayers. Therefore, their pore sizes may be governed as much by progressive 
peptide aggregation as they are by local energetics.  
In this light, poration can be described as a physical phenomenon 
accommodating peptide diffusion in the membrane matrix with no strict 
predisposition for a particular pore size, but with sufficient freedom of movement 
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for lateral expansion. To address this phenomenon in a sufficient molecular detail, 
the direct observation of pore architecture and dynamics is needed, but so far has 
been lacking. 
One reason for the lack of direct observation is the intrinsic complexity of 
imaging poration in live cells. Membrane binding of AMPs is kinetically driven and, 
in live cells, occurs over timescales of microseconds to minutes. Pores need not 
expand substantially because cell death can occur concomitantly as a result of 
membrane leakage and swelling under osmotic pressure and because AMPs can 
reach and bind to intracellular targets or disrupt processes that are crucial to cell 
viability (protein, DNA, or cell wall syntheses) within the same timescales.        
2.2.3 Imaging approach 
Biological membranes are fluid structures, yet possessing a degree of lateral 
organisation, essential for their function. Probing and, especially, imaging variations 
in the lateral composition of those biological membranes, resulting from 
interactions between membrane components as well as from the actions of 
extracellular factors interacting with the membranes, presents a major challenge.  
Membrane proteins and protein assemblies can be determined by techniques 
such as x-ray crystallography and atomic force microscopy. However, this does not 
allow the main components of the membranes, lipids, which are below 
the diffraction limits of light microscopy to be probed at molecular level. 
Fluorescence microscopy may help to overcome the issue. This technique is 
sensitive enough, though only to the fluorescently labelled components. Hence, the 
detection of only these components is possible. In addition, the introduction of 
a fluorophore may alter the properties of the labelled ligand as well as its 
interactions with membranes. Other techniques, such as infrared Raman 
spectroscopy can offer greater chemical specificity, yet again with limited sensitivity 
and lateral resolution.  
Imaging with the use of high-resolution secondary ion mass spectrometry 
(NanoSIMS) brings an advantage over those methods. The great information 
content of this technique leads to unambiguous identification of molecules by their 
mass and to visualisation of the distribution of analytes in the sample. It facilitates 
imaging based on chemical fingerprint of molecules and allows for their label-free 
analyses. Nevertheless, due to both the similarity of chemical content of different 
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biomolecules as well as complexity of biological systems, labelling with stable 
isotopes often proves necessary in the analysis of biological processes. Stable 
isotopes are ideal labels for studying biological processes because they have little or 
no effect on the biochemical properties of target molecules. NanoSIMS is a tool that 
can image the distribution of stable isotope labels with up to 50 nm spatial 
resolution, with good quantification and high sensitivity (see 5.1.4). This 
combination of features has enabled several groups to undertake significant 
experiments on biological problems in the last decade.130-133 In addition, combining 
the NanoSIMS with other imaging techniques enables obtaining not only chemical 
information but also the structural information needed to understand biological 
processes.134 
Therefore, this is the combination of Atomic Force Microscopy (AFM) and 
NanoSIMS that makes it possible to image and probe membrane-related 
interactions at the nanoscale. AFM provides information about the topography of 
samples (see 5.1.3) and can help indicate and visualise changes such as the 
structuring / destructuring effects of AMPS on the membranes. AFM gives a very 
high degree of lateral information but, since there is no chemical information, it 
does not identify the localisation of AMPs. NanoSIMS is well suited for this purpose. 
By using isotopically labelled antimicrobial peptides, imaging of the peptide 
distribution with lateral resolution of 50 nm can be achieved. This approach 
provides exquisite chemical imaging, showing both the location of the AMPs and 
the associated disorder in the lipid bilayer. Data produced by these two methods 
enable to see, measure and characterise the mode of action of AMPs.  
2.3. Imaging the action of AMPs 
This section introduces the design of a model antimicrobial peptide (AMP), 
assessment of its interactions with cellular membranes and describes 
the application of correlative AFM and NanoSIMS analysis to directly image these 
interactions. 
2.3.1 Model AMP design   
A de novo antimicrobial peptide: AMP (sequence: KQKLAKLKAKLQKLKQKLAKL -am), 
was produced. The peptide was designed as an archetypal antimicrobial sequence, 
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capable of inserting into phospholipid bilayers in a transmembrane manner and 
stimulating pore formation. The sequence design is based on a repeated heptad 
pattern, which promotes the folding into amphipathic helices.135-137  Three types of 
amino acids, in three heptads, are incorporated into the peptide sequence in a way 
to create the following repeat: CHNCHCN, where C comprises a cationic residue 
(Lysines), H – hydrophobic (Leucine) and N stands for neutral and polar (Alanine and 
Glutamine). This type of design allows the hydrophobic and polar residues to 
segregate into distinct regions (faces) upon the peptide folding during 
the interactions with anionic microbial membranes. Also, this arrangement allows 
for the formation of the helix spanning ∼3.15 nm to match the thickness of 
the membrane lipid bilayer: ∼3.2 nm138, 139 (Figure 14).  
  
 
Figure 14. Representation of AMP folding; (A) Sequence of AMP introduced as an α-helical wheel, 
with 3.6 residues per turn, showing amino acid residues clustering into three regions: cationic 
(blue residues), hydrophobic (black residues) and neutral and polar (orange residues); (B) Upon 
contact with anionic membranes the peptide folds into an α-helix, with length matching the 
thickness of the lipid membrane. 
 
2.3.2 AMP – membrane interactions 
The interaction of the designed AMP with model lipid membranes was firstly 
evaluated by circular dichroism (CD) spectroscopy. CD is a convenient technique to 
probe the secondary and tertiary structure of proteins and peptides in solution. 
Different types of secondary structures give rise to characteristic spectra, such as 
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minima values of the CD signals at 208 nm and 222 nm, which are indicative of an α-
helix (see 5.1.1).140, 141  
AMP folding was probed with the use of neutral and anionic lipid vesicles, 
mimicking mammalian and microbial membranes, respectively. 1,2-dilauroyl-sn-
glycero-3-phosphocholine (DLPC) was used to assemble neutral liposomes whereas 
its mixture with 1,2-dilauroyl-sn-glycero-3-phospho- (1’-rac-glycerol) (DLPG) at 3:1 
ratio was used to assemble the anionic ones. The liposomes were titrated into 
the peptide aqueous solution and the changes in the AMP conformation were 
monitored. The CD analysis proved that the AMP, at micromolar concentrations, 
folds into an α -helix upon interactions with synthetic membranes mimicking 
microbial surfaces (anionic liposomes). In contrast, no change in the peptide 
conformation was detected in the absence of liposomes in the solution, nor in 
the presence of neutral liposomes (Figure 15). 
 
Figure 15.  CD Spectra of AMP, revealing change in response, caused by folding of the peptide in to 
alpha-helical secondary structure upon the interaction with anionic membranes; Peptide in the in 
the absence of liposomes (red trace), in the presence of neutral membranes (blue trace), and in 
the presence of anionic membranes (green trace). Copyright © 2013, National Academy of 
Sciences, USA.  
 
Linear dichroism (LD) spectroscopy was employed to assess the relative AMP 
orientation in the model microbial membranes. LD is a straightforward method 
used to investigate alignment of molecules in solution (see 5.1.2). It gave 
an indication for the peptide insertion into AUVs in a trans-membrane manner, by 
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showing band patterns comprising maxima at 190-195 nm and 220-230 nm, and 
a minimum at 205-210 nm.142, 143 As a control Non-AMP peptide (sequence 
QIAALEQEIAALEQEIAALQ–am), which cannot bind and order in membranes, was 
also probed, for which no signal was observed (Figure 16).  
 
 
Figure 16. LD spectra, showing relative AMP orientation in membranes; Insertion into vesicles in 
trans-membrane manner (solid line), in contrast to the lack of signal observed for the non-AMP 
(dashed line). Copyright © 2013 National Academy of Sciences, USA. 
 
The designed peptides were found to be selectively antimicrobial with minimum 
inhibitory concentrations being typical of AMPs.144, 145 Given that in biological 
systems AMPs must respond to microbial challenge within their proteolytic life time 
(i.e. minutes), antimicrobial effects were monitored in real time by stain-dead 
assays using a culture of Escherichia coli. In these assays the fluorescence emission 
of propidium iodide (PI) was used as a dead cell marker and was measured after 
peptide addition as a function of time (Figure 17). As expected, just after few 
minutes increase in fluorescence in the bacterial culture treated with AMP was 
observed. In contrast, no fluorescence was observed for bacteria treated with 
a non-AMP used as a negative control (Figure 17). 
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Figure 17. Results of stain-dead antimicrobial assay; (A) Average number of stain-dead cells 
incubated with the AMP (blue) and the non-AMP (green), as a function of time. (B) Fluorescence 
microscopy images of PI-stained E. coli cells.  
 
 
Direct visualisation of AMP-treated bacterial cells by AFM revealed the surface 
corrugation of AMP-treated microbial cells. However, at this stage, more detailed 
analysis of the cell surface proved impractical due to its considerable roughness 
(Figure 18).  
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Figure 18. AFM images showing antimicrobial activity of AMP; (A) Topographic images of E. coli 
cells with and without AMP including high magnification 3D images of individual cells. (B) Low 
magnification 3D images of bacterial cells incubated with the AMP.  
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2.3.3 Nanoscale imaging 
To allow the imaging of the AMP-membrane interaction by AFM and NanoSIMS, 
which are techniques used for surface analyses, the model system had to be first 
transferred onto a surface. Schematic drawing of the sample preparation protocol is 
shown in Figure 19. Lipids mimicking microbial membranes, of the same as used 
previously composition, were deposited on an oxidised silicon substrate to form 
supported lipid bilayers. The artificial membranes were then incubated with peptide 
solution and finally dehydrated by flash-freezing and freeze-drying to preserve 
changes and peptide in the bilayer.  
 
 
Figure 19. Schematic drawing of supported lipid bilayer creation on the substrate surface. Next, 
sample is incubated with AMP, flash-frozen and freeze-dried. 
 
Supported lipid bilayer substrates were treated with AMP and then were 
imaged using AFM and NanoSIMS. Distinctive features suggesting pore formation 
were observed on the lipid bilayer surfaces. As shown in Figure 20, AFM imaging 
revealed asymmetric, circular patterns. Apart from such pores, filament-like 
features running across the sample surface were also evident, suggesting that 
peptide molecules may migrate across the lipid bilayer. Further image analyses 
indicated that the circular structures bare a shape of a crater. The diameters of 
the craters measured on the analysed sample area span from 100 nm to 350 nm. 
The depth of the craters was rather consistent and averaging 4 nm.  
Further investigation on these circular patterns was carried by NanoSIMS. 
Obtained images exposed similar patterns, when the acquired spectra were 
scanned for a characteristic 12C14N– signal (Figure 21 (A)). The analysis of untreated 
lipid bilayers, used as controls, revealed featureless surfaces and negligible signal 
from contamination on the sample (Figure 21 (B)).              
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Figure 20. Topographic AFM images and cross sections of pores created in supported lipid bilayers 
treated with AMP. 
 
 
(A)      (B)  
Figure 21.  NanoSIMS HIS images showing the intensity of 
12
C
14
N
– 
ion signal obtained from (A) lipid 
bilayer treated with AMP, (B) control lipid bilayer.  
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Next, an isotopically labelled peptide was employed. Even though the action of 
the AMP was evident from the acquired images, the label was necessary to aid 
the definitive interpretation of the obtained results. Stable isotope labelling allows 
for precise location of the peptide molecules on the sample. It also confirms that 
the changes to the sample surface are caused by the interaction with AMP rather 
than by possible mechanical damage which could occur during sample preparation. 
In biological studies, the most common stable isotopes used to label molecules are: 
2H, 13C, 15N, and 18O, which are all readily imaged by the NanoSIMS.146-149 
An isotopically labelled AMP was obtained: 15N-AMP, with 15N isotopes at all 
alanine and leucine residues (sequence: KQKL*A*KL*KA*KL*QKL*KQKL*A*KL*–am). 
The interaction of the 15N-AMP was firstly imaged by AFM, confirming the earlier 
observation of the formation of pores in the supported lipid bilayers (Figure 22). 
AFM again revealed pore-like structures of different diameters (average diameter 
2.7± 1.3 µm) and filament-like features, and showed an average step height at the 
pore edges of 3 – 4 nm, consistent with the long axis of the peptide molecule, 3.2 
nm. As negative controls, lipid bilayers treated with Non-AMP as well as bare silicon 
substrates treated with AMP were also imaged, showing no effect the peptides had 
on the analysed surfaces (Figure 23).  
Next, on the 15N-AMP treated samples NanoSIMS imaging was performed. 
The acquired images appeared to be in good agreement with those obtained by 
AFM. Secondary ion images of 12C15N– and 12C14N– signals coming from samples 
treated with 15N-AMP provided, this time, direct evidence for the precise 
localisation of the peptide both on the pore edges and in the filament-like features 
(Figure 24). The conclusions were further supported by 12C15N–/12C14N– ratio and 
hue saturation intensity (HSI) images - the sum of several sequential images to 
enhance the statistical significance of the measured signals, where 12C15N–/12C14N– 
ratios were far above natural abundance values of 0.37% (Figure 25).   
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Figure 22. Representative AFM topographic images of the 
15
N-AMP treated supported lipid 
bilayers. Copyright © 2013  National Academy of Sciences, USA. 
 
(A)     (B)              
Figure 23. AFM images of control surfaces. (A) Supported lipid bilayers treated with the non-AMP. 
(B) Bare silicon wafer substrates treated with AMP.  
 
(A)  
(B)  
Figure 24. SIMS images of pores created by the AMP and control surfaces; (A) 
12
C
14
N
–
, 
12
C
15
N
–
, and 
12
C
15
N
–
/
12
C
14
N
–
 signals from the supported lipid bilayers treated with 
15
N-AMP, (B) corresponding 
signals from the supported lipid bilayers with no peptide treatment. Copyright © 2013 National 
Academy of Sciences, USA. 
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Figure 25. SIMS image of 
12
C
15
N
–
/
12
C
14
N
–
 ratio expressed as HSI images. The rainbow scale changes 
from blue (natural abundance ratio of 0.37%) to red (40%, >100 times the natural ratio).  Copyright 
© 2013 National Academy of Sciences, USA. 
 
It was demonstrated that the undertaken approach of the combination of AFM and 
nanoSIMS imaging can be used to visualise the action of the peptides with lipid 
membranes. What was also noticed is that the poration caused by AMP is not 
limited to a particular pore size. The forming pores are expanding in the sizes 
spanning the nano-to-micrometer scale. The appearance of peptide-rich filament-
like structures on the sample the surface, connecting individual pores, points to 
the probability of peptide migration across the bilayer surface.   
To confirm that the poration mechanism in not transient, the dynamics of 
the peptide migration in the membrane has been next probed by performing real 
time AFM imaging in liquid. Low concentration AMP solution was introduced 
directly into a liquid cell containing supported lipid bilayer deposited on a mica 
substrate. The small pores started forming after the first 10 min of incubation and 
continued multiplying and growing in size over the time, resulting in total removal 
of the lipid bilayer from the substrate surface (Figure 26, Figure 27). These results 
indicate that pores can expand laterally at the nano-to-micrometer scale leading 
eventually to complete membrane disintegration. 
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Figure 26. Topography images from real-time, in-liquid AFM imaging of supported lipid bilayer 
treated with AMP. Copyright © 2013 National Academy of Sciences, USA 
 
 
    
Figure 27. AFM topography image of the supported lipid bilayers after 40-min incubation with 
AMP. On the right presented are corresponding pore cross-sections along the highlighted on the 
AFM image lines. Copyright © 2013 National Academy of Sciences, USA. 
2.4. Conclusions  
De novo designed peptide with antimicrobial properties was investigated to probe 
selective cellular membrane targeting. The interactions of the AMP with lipid 
bilayers, mimicking microbial and mammalian cell membranes were analysed by 
molecular biophysics. The results confirmed that the AMP interacts differentially 
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with the model bilayers. The peptide does not expose destructive effects towards 
mammalian membranes and, at the same time, possesses effective antibacterial 
properties, as confirmed by microbiological studies. 
The ultimate aim is to use engineered peptides as ligands in functionalised 
nanoparticle-based probes. Since antimicrobial peptides distort bacterial 
membranes, this research concentrated on the elucidation of the mechanism of 
these interactions.  
The dominant molecular model for antimicrobial action has been based, to 
date, on the formation of stable or transient pores. The obtained by the project 
results proved otherwise.  The interactions of the de novo designed archetypal AMP 
were imaged by the combination of AFM and stable isotope imaging by NanoSIMS. 
This enabled high-resolution visualisation of the topography of peptide-treated 
membranes, complemented by chemical imaging which revealed the precise 
localisation of peptide molecules in the membranes. The acquired images showed 
that pores formed by antimicrobial peptides in supported lipid bilayers are not 
necessarily limited to a particular diameter, nor they are transient, but can expand 
laterally at the nano-to-micrometer scale to the point of complete membrane 
breakdown. The latter was endorsed further by real-time AFM imaging in liquid.  
The correlative AFM and NanoSIMS imaging allowed monitoring and analysis 
at the much-desired nanoscale. Bearing in mind the intended use of nanomaterials 
to create peptide-based nanoprobes this makes this combination highly beneficial. 
This research provides a strong base for the further use of peptide rational design 
for specific cell surface and trans-membrane targeting as well as the creation of 
nanoparticle conjugates with molecular peptide ligands. 
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  CHAPTER 3
CELLULAR UPTAKE OF CELL PENETRATING PEPTIDES 
 
3.1. Summary 
The previous chapter described the effect of antimicrobial peptides on bacterial cell 
membranes. This part focuses on the study of interactions of membrane-active 
peptides with mammalian cells. This chapter presents the implementation of 
a minimalistic approach, based on multidimensional chromatography followed by 
mass spectrometry, to quantify the cellular uptake of cell penetrating peptides 
(CPPs), bearing in mind the ultimate aim of using the peptides as model ligands to 
functionalise NPs for intracellular targeting and delivery. The work described here, 
resulted in the following publication: ‘Probing label-free intracellular quantification 
of free peptide by MALDI-ToF mass spectrometry’, P D Rakowska, B Lamarre, 
M G Ryadnov; Methods, 2014, 68 (2), 331-337150, which can be found in the 
‘Publications from the project’ section of this thesis.  
3.2. Introduction  
3.2.1 Cell penetrating peptides 
Membrane-active peptides, studied in this project, are able to interact with both 
antimicrobial and mammalian cell membranes. However, the membrane type 
influences the particular effect of those interactions. The main difference between 
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bacterial and mammalian membranes lies in their lipid composition. Microbial 
membranes are built from anionic lipids, while mammalian cells contain 
predominantly zwitterionic species. As previously described, antimicrobial peptide 
actions are non-selective and aimed at the membrane disruption with cytolytic 
effect. The same peptides can expose, however, cell penetrating properties when in 
contact with mammalian cells. In this setting they turn, from antimicrobial, to cell 
penetrating peptides (CPPs). 
The role of the CPPs is to deliver the cargo into cells. The carried material can 
be associated with the peptides either via covalent bonds or via non-covalent 
interactions. Most known, naturally occurring CPPs are not cell type specific, and 
their interaction with mammalian cell membranes as well as penetrating properties 
rely primarily on their positively charged, at physiological pH, amino acid sequences 
and electrostatic interactions with subtly anionic cell-surface molecules. Increasing 
number of reports suggest that the CPP intracellular delivery is governed by 
endocytosis, which is then followed by the endosomal escape and release of 
unmodified cargo.32, 151, 152 Schematic representation of the process is presented by 
Figure 28. 
CPPs hold great potential as gene or drug delivery mediators, for use in 
medicine and research. They facilitate cellular uptake of various molecular moieties 
i.e. small chemical molecules, fragments of nucleic acids or nanosize particles. By 
further manipulating their properties towards selectivity for particular cell 
compartments or components, classes of novel drugs and antibiotics or specific 
probes could be devised. One example could be peptides engineered as an efficient 
nucleic acid (NA) delivery system (Figure 28). These type of peptides should be able 
to (i) efficiently condense NA into compact particles, (ii) transfer the NA across 
cellular membranes in the process of endocytosis, (iii) induce endosomal peptide 
escape and (iv) target the NA cargo to the nucleus for gene expression.153 
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Figure 28. Conceptual illustration of intracellular transport pathways encountered by a model 
nuclear targeting delivery system incorporating fusogenic peptides as means of endosomal escape. 
Reprinted with modification from Huang, et al., Nano Today, 2011.
154
 Copyright © 2011, with 
permission from Elsevier. 
 
3.2.2 Quantitative approaches 
The quantification of the cellular uptake of CPPs remains largely inconclusive. 
CPPs can efficiently traverse the plasma membrane and deliver various cargo 
materials but the functional efficiency of cargo often depends on the completeness 
of intracellular peptide uptake. Therefore, before CPPs can be used as robust and 
specific delivery agents or used to create functionalised molecular probes for 
intracellular targeting, it is important to firstly understand, characterise and 
quantify their uptake. Current quantification methods use fluorescent or radioactive 
reporter probes that are monitored by fluorescence microscopy and mass 
spectrometry.151, 155 These appear to help quantify the CPPs uptake. However, 
controversies remain regarding discordant results in different studies and the need 
for artificial labelling, which continue questioning the general applicability of these 
methods.156  
To progress with quantification necessitates the development of direct 
detection protocols. A notable example is quantification by MALDI TOF mass 
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spectrometry, briefly described in CHAPTER 1 of this thesis.77 This protocol makes 
use of an internal standard labelled with a stable isotope. The standard and 
the detected analyte are both functionalised with biotin which ensures their 
capture by streptavidin-coated magnetic beads and subsequent pre-concentration 
and purification before mass spectrometry analysis. With typical variations of < 20% 
the protocol has no upper limits of detection which can also be adjusted by the 
amount of the internal standard added. A critical stage in these measurements is 
the addition of the standard into cells before cell lysis which is performed at 
elevated temperatures. Heating is meant to prevent peptide degradation by 
proteases that are released during cell lysis but become denatured upon heating. 
The following capture by streptavidin-coated magnetic beads should be equally 
efficient for the standard and analyte that are prone to the same type of side 
interactions, i.e. with nucleic acids.77 However, elevated temperatures can cause 
aggregation that may hamper the capture and analysis of the internalised peptides, 
whereas the transfection efficiency of a tagged peptide may be different from that 
of its free form. These points are important to consider in the development of 
quantitative protocols to be sufficiently generic for intracellular drugs including 
those that are thermally labile or for which introducing a tag is not acceptable.157  
Unless the total peptide recovered from cell lysates can be estimated it 
remains difficult to benchmark tag-based methods. Surprisingly however, little 
information is available with regards to the intracellular quantification of free intact 
peptide from cell lysates. This chapter introduces a strategy which intends to fill this 
gap. This chapter compares the transfection of a de novo design CPP with that of 
a naturally occurring cell penetrating peptide, TaT (HIV Trans-Activator of 
Transcription (Tat) protein). It probes free peptide concentrations, recovered from 
cell lysates using multidimensional liquid chromatography combined with isotope 
dilution MALDI mass spectrometry, without the use of labels, tags or specialist 
reagents (Figure 29). This method offers a minimalistic approach for intracellular 
quantification, which can be used as a correlative measure for fluorescence-based 
imaging methods. 
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Figure 29. Schematic representation of the quantification method based on a LC-MS flow; 
Transfected with CPP cells are subjected to cell lyses. Cell lysate is fractionated by SEC, from where 
fractions are processed by RP-HPLC. To the fraction containing CPP isotopically labelled analogue 
of the peptide is added. The detection of the peptides is done by MALDI MS and concentration of 
the CPP is back-calculated based on the peptides’ signal intensity ratios. Copyright © 2014, with 
permission from Elsevier. 
3.3. Quantification of cellular uptake of CPPs  
3.3.1 Model cell penetrating peptides  
De novo designed peptide with cell penetrating properties: CPP (sequence: 
KIAKLKAKIQKLKQKIAKLK-am) was used in this study. In practice, the described in 
preceding chapter AMP could serve as a cell penetrating peptide model. However, 
to enhance the cell penetrating properties, cargo carrying ability and endosomal 
release, the sequence of previously used AMP was altered. The rational design of 
the peptide has been described by Lamarre et al. 32  
 
Similarly to the de novo AMP, the sequence design of the CPP was based on 
a repeated heptad pattern, which promotes the formation of amphipathic 
helices135-137, allowing the hydrophobic and polar amino acid residues to segregate 
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into distinct regions upon the peptide folding during the interactions with cellular 
membranes (Figure 30). The designed AMP and CPP are nearly equally sized and of 
similar amino acid composition. However, CPP comprises a combination of 
hydrophobic isoleucine and leucine residues, as opposed to the AMP containing 
leucine only in its hydrophobic face. This limits the potential peptide aggregation to 
assembly of lower oligomers.124, 125 Neutral face of the folded peptide does not 
contribute to membrane binding but promotes efficient condensation of nucleic 
acids. In addition, a lysine sub-face is incorporated within the neutral region of 
the helix to enable and balance out the efficient nucleic acid binding without 
compromising the interaction with the membrane (Figure 30).  
 
 
Figure 30. Representation of CPP folding; CPP sequence introduced as (A) an α-helical wheel and 
(B) an helical net plot, showing amino acid residues clustering into three regions: cationic (blue 
residues), hydrophobic (black residues) and neutral and polar (orange residues).   
 
The properties of the CPP were evaluated by Lamarre et al.,32 proving it to be 
an effective gene transporter. The preferential binding to anionic membranes 
(bacterial  and  acidified  endosomal)  was probed by CD and LD spectroscopy 
(Figure 31) and microbiology assays. The CPP undergoes differential membrane-
induced folding, providing a strong antibacterial response. This renders it both 
endosomolytic and antibacterial. The cell-penetrating ability and NA-delivery 
properties were monitored by fluorescence microscopy using HDFa cells.32 
The peptide penetrates eukaryotic cells and promotes active DNA transport into 
mammalian cells by undergoing receptor-independent mammalian cell entry.  
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Figure 31. CPP folding probed by circular and linear dichroism; (a) CD spectra for GeT in 10 mM 
phosphate buffer (white squares) and with anionic (solid line) and zwitterionic (black squares) 
membranes: pH 7.4, 4 mM peptide. (b) LD spectra for GeT (solid line) and non-GeT (black triangles) 
with anionic membranes, 30 mM peptide. Adapted with permission from Lamarre et al.; Chem 
Commun  2011.
32
 Copyright © 2011 the Royal Society of Chemistry. 
 
 
Using the earlier established imaging methods, the antimicrobial activity of the CPP 
was also probed by the real-time AFM imaging. The analysis confirmed similar, to 
the previously probed AMP, mode of antimicrobial action (Figure 32). After several 
minutes of treatment of supported synthetic microbial membranes with the CPP, 
creation of small pores can be observed on the sample surface. The pores multiply 
and continue growing, leading eventually to the complete lipid bilayer 
disintegration.  
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Figure 32. In-liquid AFM imaging of CPP-treated supported lipid bilayers. The circle highlights a 
pore. Colour scales (insets) from left to right: the first three are3 nm, the last one is 8 nm. 
 
For comparison and as a positive control, naturally occurring peptide (TaT) was also 
employed in the study (sequence: YGRKKRRQRRR-am). The peptide is a transduction 
domain (TaT 47-57) of a HIV-Trans-Activator of Transcription (HIV-Tat) protein, 
which is well characterised and known to carry cell penetrating properties. 
However, unlike the designed CPP this peptide is not able to escape endosomes into 
the cytoplasm.137, 158-161 
3.3.2 Transfection evaluation by confocal microscopy 
To be able to compare and correlate the proposed quantification approach to 
the fluorescence-based imaging methods the uptake of CPP and TaT was firstly 
evaluated by confocal-fluorescence microscopy. Confocal microscopy is a powerful 
tool in imaging of cell samples in situ. It enables the fluorescence monitoring of 
fluorophore-labelled ligands in real time. Both peptides were labelled with 
a standard fluorophore (CPP-Flu and TaT-Flu), carboxyfluorescein (Figure 33), 
commonly used as a tracer agent for fluorescence based analysis.  
 
 
 
Figure 33. Chemical structure of carboxyfluorescein. 
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Human Dermal Fibroblasts (HDFa) were incubated with CPP-Flu and TaT-Flu. 
Visible fluorescence in cells was detected within the first hour of incubation at 
micromolar concentrations for both peptides. It was dominated by punctuate 
staining, pointing to their endocytic uptake (Figure 34). Longer incubations, up to 24 
hours, revealed more apparent differences in the fluorescent patterns of the two 
peptides suggesting differential accumulation. The peptides do not accumulate in 
the nucleus, which implies that transfection was not nucleus-specific and did not 
lead to cytotoxicity. While CPP-Flu fluorescence tended to disperse in the 
cytoplasm, that of TaT-Flu continued being vesicularly localised (Figure 34 & Figure 
35). These results are consistent with previous studies and with that CPP efficiently 
escapes into the cytoplasm by permeabilising endosomal membranes, whereas TaT 
remains entrapped in the endosomes.32, 162 Incubations with free 
carboxyfluorescein used as a negative control gave no fluorescence.  
Comparative analysis of transfection, as a function of fluorescence at 
a constant peptide concentration, was carried out. Incubation of the cells in 10 µM 
peptide solutions revealed that 10% of total cells were transfected within the first 
hour for both peptides. Increases to 70 and 90% of total transfected cells were 
observed within 3 hours for TaT-Flu and CPP-Flu, respectively (Figure 36). The 20% 
difference between CPP-Flu and TaT-Flu appeared to be consistent with the more 
dispersed fluorescence of CPP-Flu (Figure 34, Figure 35). Transfection of all cells was 
complete within the first 8 hours of incubation. 24-hour incubations, which were 
within the first cell doubling time, gave 15 and 30% decreases in fluorescence for 
CPP-Flu and TaT-Flu (Figure 36). 
 
 
Figure 34. Confocal fluorescence micrographs of HDFa after 3-hour incubation with peptides. 
Copyright © 2014, with permission from Elsevier. 
  
 
78 
 
CPP-Flu     TaT-Flu 
  1 h      
  3 h      
  8 h      
24 h      
Figure 35.  Transfection monitoring; confocal fluorescence micrographs of HDFa incubated with 
10 M CPP-Flu and TaT-Flu. The micrographs were taken at different time points of incubation. 
Copyright © 2014, with permission from Elsevier. 
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Figure 36. Transfection efficiency as a function of relative fluorescence intensity per cell; total 
fluorescence divided by the total number of cells. Copyright © 2014, with permission from 
Elsevier. 
 
3.3.3 Quantification by isotope dilution LC-MALDI  
Fluorescence studies showed that efficient peptide translocation is reached within 
the first 3 hours. Therefore, the same transfection conditions were used for free 
peptides to probe their quantification from transfected cell lysates. Two-
dimensional chromatographic separation preceding mass spectrometry analysis was 
applied. SEC was chosen to allow for the pre-fractionation of lysate samples which 
was then followed by an off-line RP-HPLC purification of the concentrated and 
reconstituted SEC fractions (Figure 29). 
 
Following incubation of Human Dermal Fibroblasts (105 cells in the culture) 
with CPP and TaT solutions, the cells were washed and subjected to cell lysis. Two 
protocols of cell lysis were considered: first with the use of Triton-X 100 solution 
and second with the use of Rapigest detergent, as described in the methodology 
section. The use of the Rapigest protocol seemed somewhat advantageous because 
it allows for the removal of DNA from cell lysates prior to further analyses and 
hence can improve the separation of compounds during the following SEC 
fractionation. However, as tested further by RP-HPLC and MALDI MS, CPP was not 
detectable in any of the collected fractions (Figure 37). Since this peptide is known 
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to bind DNA32 it is believed it has been extracted from the sample together with 
the DNA.  In contrast, Triton-X 100 proved highly efficient. This non-ionic surfactant 
enables complete disintegration and denaturation of cellular structures at very low 
concentrations. 
 
Figure 37. SEC chromatogram of the CPP-transfected HDFa lysates obtained from Triton X 
treatment (red trace) and from Rapigest treatment (blue trace). Marked is the retention time, 
during which the peptide was expected to elute and the fractions were collected for further 
analysis. 
 
Indeed, SEC of processed Triton-X 100 lysates of non-transfected cells and the same 
lysates spiked with GeT or TaT at known concentrations revealed components with 
lower molecular sizes than the peptides. Figure 38 shows representative 
chromatograms obtained for CPP. Peptide peaks on the chromatograms obtained 
for pure peptide samples and peptide-spiked lysate samples had comparable 
intensity and area values suggesting that no stable complexation between 
the peptide and other components in the lysates occurred (Figure 38). SEC profiles 
for Triton-X 100 lysates of the transfected cells were nearly identical to those 
obtained for the peptide-spiked lysates (Figure 37 & Figure 38). The fractions at 
the same retention time showed a somewhat larger peptide content, which may be 
attributed to other lysate components eluting at the same time (data not shown).  
 
Retention time [min] 
5 10 15 20 25 30 
AU 
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Figure 38. Separation of CPP by SEC; Chromatograms of 10 µg CPP (green trace), 1 µg CPP (blue 
trace) and spiked with CPP cell extract containing 10 µg of CPP (red trace). Marked is the retention 
time, during which the fractions were collected for further analyses. Copyright © 2014, with 
permission from Elsevier. 
 
The collected during SEC analysis fractions containing CPP and TaT were 
concentrated and re-purified by analytical RP-HPLC. RP-HPLC traces of 
the reconstituted SEC fractions for CPP revealed clear peaks at retention time of 
14.7 min corresponding to the elution time of pure CPP peptide (Figure 39). No 
trace of TaT peptide was observed during the RP-HPLC separation (Figure 40). This 
is, most likely, due to the lower value of extinction coefficient, at the 214 nm 
wavelength, in comparison to the extinction coefficient of CPP. Nevertheless, 
further MALDI MS analyses of the collected RP-HPLC fractions confirmed 
the presence of both the peptides in the collected fractions, confirmed at the same 
time the peptide identities (data not shown).  
Retention time [min] 
5 10 15 20 25 30 
AU 
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Figure 39. RP-HPLC analyses of SEC fraction containing CPP; Analysis of the Triton cell lysate from 
HDFa transfected with the CPP. The elution of CPP is marked by the red circle. 
 
 
Figure 40. RP-HPLC of sample containing TaT. The chromatogram shows the analysis of SEC 11
th
 
minute-fraction from Triton cell lysate. Expected retention time of TaT marked.  
 
 
Retention time [min] 
5 10 15 20 25 30 
AU 
Retention time [min]   
5 10 15 20 25 30 
AU   
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To enable the quantification of peptides by MALDI mass spectrometry, isotopically 
labelled analogues of CPP and TaT were produced (CPP-H and TaT-H, respectively), 
where one of the amino acids in the peptides sequences: leucine at the position 19 
(in CPP) and glutamine at the position 5 (in TaT) were 13C / 15N isotopically labelled 
(Figure 41). 
 
        KIAKLKAKIQKLKQKIAKL*K-am     YGRKKRRQ*RRR-am 
                               
 
   
Figure 41. Labelled sequence residues and chemical structures of: A) Leu 6C13N15 and B) Glu 
5C132N15, used for labelling of CPP and TaT, respectively.  
 
 
The RP-HPLC peptide fractions were spiked with an appropriate peptide analogue 
and the amounts of the internalised intact peptide were determined by MALDI MS 
using prior-built standard curves (see 5.2.3 ‘Isotope dilution standard curves’). 
The prepared curves plot the ratio of the intensity of the peptide ion to the heavy 
analogue  ion  intensity  against the concentration of the peptide (Figure 42 & 
Figure 44). Representative MALDI MS spectra of the analysed samples, to which 
heavy peptide analogues were added, can be found in Figure 43 and Figure 45. 
 
A) B) 
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Figure 42. The quantification standard curve of CPP, with indicated in red, calculated average CPP 
concentration recovered from cell lysate. Error bars represent % standard deviation. Copyright © 
2014, with permission from Elsevier. 
 
 
Figure 43. MALDI MS spectra showing the final detection of CPP (2318 Da) in the spiked with the 
CPP-H (2325 kDa) RP-HPLC fraction. Copyright © 2014, with permission from Elsevier. 
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Figure 44. Standard curve for the quantification of TaT. Calculated average TaT concentration 
recovered from cell lysate is indicated in red. Error bars represent % standard deviation. Copyright 
© 2014, with permission from Elsevier. 
 
 
Figure 45. MALDI MS spectra for RP-HPLC TaT fraction (1558 Da) spiked with the TaT-H (1556 kDa). 
Copyright © 2014, with permission from Elsevier. 
 
The amounts of the peptides in the RP-HPLC fractions were calculated. The returned 
values of 0.63  0.08 pmol and 0.59  0.08 pmol for CPP and TaT, respectively, were 
found to be at approximately 14  1.7% (CPP) and 13.1  1.7% (TaT) of the total 
peptide used for the quantification. Thus, 1.4  0.17 M peptide was recovered 
from 105 cells incubated with 10 M peptide for 3 hours. The recovered 
y = 1.5573x - 0.7849 
R² = 0.9881 
-6
-4
-2
0
2
4
6
8
10
0 1 2 3 4 5 6R
e
la
ti
ve
 I
n
te
n
si
ty
 
Ta
T-
N
/T
aT
-H
 r
at
io
 
TaT-N concentration [pmol/ul] 
  
 
86 
 
concentration corresponds to a total intracellular concentration of 3.7  0.06 M at 
the intracellular volume of 3.4 pL per cell.163, 164 Quantifications using this protocol 
gave reproducible results with typical variations of <15%, which are within the 
reported 5-20% ranges.77  
The obtained results allow also correlations with fluorescence data. In this 
case, the ~2 µM intracellular concentrations found for 3-hour incubations 
correspond to 70% and 90% of total fluorescent cells for TaT and CPP, respectively. 
The microscopy data, which relies entirely on fluorescence, suggests that CPP is 
more efficient, while mass spectrometry does not fully support this.  Instead, it 
indicates that CPP is as efficient in penetrating human fibroblasts as TaT. 
Interestingly, however, the results are consistent with the broader distribution of 
fluorescence in the cytoplasm for CPP.  
3.4. Conclusions 
This part of the project concentrated on the study of interactions of membrane-
active peptides with mammalian cells. Toward the aim of the development of 
peptide functionalised nanoprobes, model cell penetrating peptides were used to 
investigate targeted intracellular delivery and endosomal release. De novo 
engineered CPP and naturally occurring TaT, were used and compared in the study. 
Human Dermal Fibroblasts, transfected with the model, fluorophore-labelled 
peptides were monitored by confocal fluorescence microscopy. Results showed 
different fluorescent patterns for the two peptides, suggesting their differential 
accumulation within the cells.  While CPP tended to disperse in the cytoplasm, TaT 
continued being vesicularly localised. These results confirmed that the de novo 
design of CPP promotes peptide escape to into the cytoplasm by permeabilising 
endosomal membranes. TaT peptide remained entrapped in the endosomes.   
Focus was given to the intracellular quantification of the two cell-penetrating 
peptides. Existing quantitative approaches rely on the use of radioactive and 
fluorescent labels or tags which allow colorimetric, fluorescent or spectrometric 
detection, but lack the ability to detect free peptide. Therefore, the aim of this 
study was to quantify free peptide concentrations recovered from cell lysates 
without the use of labels, tags or specialist reagents. The applied strategy was also 
compared to the results obtained by fluorescence analysis.  
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A multidimensional quantification approach was implemented and validated. 
The method consisted of combination of liquid chromatography and isotope 
dilution mass spectrometry. To allow accurate peptide analysis by matrix assisted 
laser desorption / ionisation mass spectrometry (MALDI MS) isotopically-labelled 
analogues of cell penetrating peptides were used as reference standards. 
The quantities of designed and naturally occurring peptides internalised in primary 
cells were measured. Determined peptide concentrations were similar to those 
reported for cell-penetrating peptides used to transfect other cell lines.155 Similar 
values for a more basic (than TaT) CPP could be attributed to several factors 
including peptide complexation with lysate components, degradation and material 
loss during purification and processing. However, the same protocol was used for 
both peptides. CPP had broader distribution in the cytoplasm than TaT, which 
tended to remain in endosomes, and may also have higher affinities to phospholipid 
membrane components and nucleic acids.32      
Several advantages of the applied method can be pointed out. Firstly, it is 
label- and tag-free – only free peptide is used, isolated and quantified. This is in 
contrast to other methods including those based on MALDI-ToF quantification that 
use biotin-tagged peptides and introduce labelled standards before lysis, which in 
itself can lead to additional uncertainties regarding the concentration of 
the standard.77, 155 Secondly, it is performed at benign temperatures, which 
eliminates potential artefacts associated with peptide aggregation. Thirdly, it gives 
a realistic estimation of recoverable peptide concentrations using a minimalist 
approach that can be readily replicated by others without specialist materials. 
Nevertheless it can be also used as a correlative measure for fluorescence-based 
imaging methods. 
The obtained results were reproducible and suggest that, under applied 
experimental conditions, the designed CPP is similarly efficient in terms of cell entry 
in comparison to the naturally occurring TaT. This observation is promising in terms 
of the rational design of efficient exogenous peptide biomarkers and peptidic 
delivery vectors.  
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  CHAPTER 4
NANOPROBE DEVELOPMENT AND ITS ASSESSMENT IN 
BIOLOGICAL SAMPLES 
 
 
                             
4.1. Summary 
This chapter describes generic nanoprobe models. The models comprise metal 
nanoparticle with surfaces passivated by lipid bilayer and polyethylene glycol 
coatings, and functionalised with designed cell penetrating peptides. The ability of 
the created probes to interact with mammalian cells is investigated by transmission 
electron microscopy.  
4.2. Introduction 
There is a demand for more robust, sensitive and reliable tools to enable 
intracellular delivery as well as the detection of biomarkers present in cells. 
Platforms aiding in quantitative determination, targeted drug delivery and 
simultaneous imaging are of particular interest. The development of such 
technologies would improve not only early diagnosis of diseases but also their 
therapy and monitoring of progress.  
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Nanoparticles could underpin the development of very specific and sensitive 
platforms. They present a diverse class of nanoscale materials. As described in 
CHAPTER 1 of this thesis, their surfaces can be modified to create highly selective 
adsorbing species or to incorporate any desirable molecule. Nanoparticles can be 
functionalised with multimodal components, serving multiple purposes in various 
biological assays. Targeting moieties such as de novo designed peptides can be 
conjugated to the particle surface. Nanoparticles can also be utilised in drug 
delivery. Furthermore, the incorporation of multiple imaging modalities is also 
possible.  
Cell penetrating peptides can assist targeted intracellular delivery of the 
nanoparticles, hence the variety of ligands that can also be to the particles 
conjugated. The unspecific mode of action of CPPs towards mammalian cells has 
already led to the design of various peptide-based delivery platforms, as 
exemplified in Figure 46. By the application of rational peptide design and by 
merging peptide marker with nanoparticle system into a single bio-functional 
platform one could enable a transfer targeted to specific tissues, cell types or 
cellular compartments. 
One main obstacle, when working with metallic nanoparticles arises from 
the nanoparticle properties. Complex biological samples, such as cells, cellular 
extracts or serum, contain many different components, which can react with 
the nanoparticle surface. Therefore, before particles can be used for analysis in such 
systems their surfaces should be passivated to prevent non-specific interactions. For 
example, lipid bilayer coverage around nanoparticle can be utilised to increase 
the particle stability and prevent undesired physisorption. Polyethylene glycol (PEG) 
coating can provide bio-inert properties and prolong the nanoparticle life in 
biological systems such as cells or blood.165, 166  
This chapter describes the functionalisation of metallic nanoparticles with 
surface-passivation coatings, to which designed model peptides of cell penetrating 
properties are next conjugated. The employment of nanoparticles in the study 
enables their direct imaging (without the need of additional tags or staining) by 
transmission electron microscopy. Therefore, the ability of the created probes to 
interact with mammalian cells is investigated by this technique. The platform forms 
a base for the fabrication of nanoprobes, which can be readily conjugated with 
peptidic moieties with desired properties and specific activities, resulting in specific 
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bio-molecular markers, intracellular cargo delivery or selective biomarker targeting 
and binding.  
 
 
Figure 46. Applications of cell-penetrating peptides as molecular delivery vehicles for a variety of 
drugs, nucleic acids, proteins, therapeutics, and imaging agents. Adapted from E. Koren and V. P. 
Torchilin, Trends in Molecular Medicine, 2012.
167
 Copyright © 2012, with permission from Elsevier. 
4.3. LipoNP 
To prevent unspecific binding of undesirable molecules to NP surfaces, 
an investigation of covering the particles with lipid bilayer was carried out. 
A method was developed, based on the conjugation of thiol-modified lipids onto 
the NP surface. This resulted, firstly, in a NP encapsulated in an inverted lipid 
micelle. Next, the second lipid was added to form lipid bilayer around the particle.  
 
Head group modified thiol-lipid: 1,2-dipalmiotyl-sn-glycero-3-phosphotioethanol 
(DPPTE) (Figure 83) was coupled to silver nanoparticles (AgNPs) of sizes: 10 nm and 
20 nm, using the high affinity of the thiol group to silver. The initial coupling of 
the thiol-lipid to silver was performed in two solutions: water and chloroform. 
The two solutions were probed to assess the best conditions for the reaction, 
bearing in mind planned further steps of nanoparticle coating and also, taking into 
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consideration the insolubility of DPPTE. Next, the experiments concentrated on 
adding the second lipid: DLPC (Figure 79) and creating a lipid bilayer around the 
AgNPs. The production of the construct (lipoNP) took place between two phases: 
aqueous-water and organic-chloroform (Figure 84). To exclude the question if DLPC 
reacts with AgNPs, additional experiment was conducted, where in place of 
the DPPTE, DLPC was employed.  
 Firstly, NPs encapsulated in inverted lipid micelles were evaluated. Two 
different preparations of the complex were carried out: (1) in chloroform and (2) in 
water.  
When only chloroform was added to the initial AgNPs solution, the NPs 
remained in the aqueous phase. When the chloroform solution of DPPTE was mixed 
with the AgNP aqueous solution, the colour of the aqueous phase, yellow/brown, 
was immediately transferred to the organic phase, indicating that the AgNPs 
became soluble in chloroform via coupling with DPPTE (Figure 47, Figure 49 B). 
The complex in chloroform seemed to be stable. However, the separation by 
centrifugation of the DPPTE-conjugated 10 nm AgNPs appeared to be difficult, while 
being very efficient for the 20 nm ones.  
 
 
Figure 47. Scheme of inverted micelles creation. AgNPs, upon reaction between Ag and the 
sulfhydryl group of DPPTE, are being transferred from the aqueous solution to the organic phase, 
which contains excessive amount of the thiol-lipid. Finally, the AgNPs surface is completely 
covered with the lipid residues.  
 
Preparation of the complex in water resulted differently. The milky suspension of 
DPPTE disappeared after mixing with AgNP and the solution gained transparency, 
suggesting the conjugation of the lipid onto the NP surface. Nevertheless, 
aggregation of the complex occurred, as judged by the solution colour change. 
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20 nm AuNPs aggregated more rapidly. MALDI MS and DLS measurements have 
confirmed the presence of lipid dimers and trimers as well as larger aggregates in 
the solutions (data not shown).  
Further experiments concentrated on covering the micelles with the second 
lipid – DLPC; DLPC resuspended in water was added to the pellet of DPPTE-AgNPs 
conjugates (kept in few drops of chloroform). After vigorous shaking and sonicating 
of the mixture, the gain of the colour by the aqueous phase of the solution 
indicated the transfer of the DPPTE-AgNPs to the aqueous phase, as a result of the 
conjugates being covered by the layer of DLPC (Figure 48, Figure 49D). In a parallel 
experiment, DPPTE was replaced by DLPC and, as expected, it was not possible to 
transfer AgNPs from aqueous solution to the organic phase containing the lipid 
(Figure 49 B and C).   
 
 
 
Figure 48. Drawing presenting the creation of the second lipid layer. AgNPs, covered with DPTTE in 
a form of inverted micelles, upon mixing with the aqueous solution containing DLPC are being 
transferred from chloroform to the aqueous phase. Finally, the AgNPs surface is covered with the 
lipid bilayer, giving LipoNP. 
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(A)     (B)  
 
(C)     (D)  
 
Figure 49.  Production of AgNPs covered by lipid bilayer; (A) aqueous phase of AgNPs added to 
lipids dissolved in chloroform (right: DPPTE, left: DLPC); (B) colour change of the organic phase 
containing DPPTE due lipid-NP complexation; (C) after centrifugation DPPTE-AgNP form a pellet 
(left), while DLPC still remains in the aqueous phase (right); (D) DLPC solution added to the DPPTE-
AgNP pellet – gain of colour indicates the bilayer formation.  
 
 
Dynamic Light Scattering (DLS) measurements were used to assess 
the lipoNPs. DLS is a technique, which can be used to measure the size as well as 
the size distribution of particles held in suspension (see 5.1.6). The performed 
measurements suggested the necessity of construct extrusion. In the initial solution 
agglomerates of the LipoNPs were observed, as judged by the size distribution by 
intensity and volume (Figure 50). The agglomerates disassembled notably after 
passing, several times, through 50 nm pore size membrane (Figure 50).  
Additionally, it was noted that LipoNPs construct proved stable in aqueous 
solutions and during repeated extensive centrifugation, which allows its efficient 
purification and recovery. 
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Figure 50. DLS measurements showing the difference between bare AgNPs 20 nm (red trace), 
lipo-AgNPs 20 nm without any treatment (green trace) and lipo-AgNPs 20 nm after extrusion 
through 50 nm pore size membrane (blue trace). The size distribution of particles in the samples is 
presented by intensity (top panel), volume (middle panel) and number (bottom panel). 
 
Finally, the effectiveness of the nanoparticle surface passivation approach was 
probed. The lipoNPs complex was incubated with serum sample. In a parallel 
experiment bare AgNPs were employed as a control.  After the incubation particles 
were recovered from the serum solution by centrifugation and, following several 
washing steps, introduced to MALDI MS analysis. The analysis revealed severe 
physisorption of serum compounds to the bare particles. Differently, in the case of 
the LipoNP construct, no unspecific binding was observed (Figure 51). This indicates 
the efficient passivation properties of the lipid bilayer. 
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Figure 51. MADLI MS spectra of: A) bare AgNPs after incubation with serum B) lipoNPs after 
incubation with serum – the insert shows the spectrum normalised to the highest intensity ion.  
4.4. Nanoprobe fabrication 
The constructed LipoNPs proved to be stable and passive in terms of the surface 
non-specific binding. Therefore, the attempt was made to additionally functionalise 
the LipoNPs with the previously studied cell penetrating peptide (CPP), with 
the goal of developing a generic nanoprobe model. In parallel, an alternative 
approach to functionalise nanoparticles with CPP was also carried out, where 
polyethylene glycol (PEG) was used instead of the lipid bilayers. 
 
The well-established cross-linker: 4-(N-maleimidomethyl)cyclohexane-1-carboxylic 
acid 3-sulfo-N-hydroxysuccinimide ester (SMCC) (Figure 52) was used as coupling 
moiety. SMCC is a heterobifunctional reagent, which incorporates an extended 
spacer with both sulfhydryl and amine reactivity. SMCC can form amide bonds with 
primary amines and can couple molecules containing free sulfhydryl group via 
thioether bond.168 
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To enable the attachment of CPP to LipoNPs via SMCC, the CPP was extended 
with one cysteine at the N-terminus (CKIAKLKAKIQKLKQKIAKLK-am). Also, the DLPC 
making up the outer layer on the LipoNPs was replaced by 1,2 dilauroyl-sn-glycero-
3-phosphoethanolamine (DLPE) (Figure 85), which contains a primary amine group.   
 
 
Figure 52. Chemical structure of SMCC. 
 
 
Schematic representation of the LipoNP functionalisation process is shown in 
Figure 84. The protocol consists of four steps. Firstly, AgNPs are conjugated with 
thiol-modified lipid (DPTTE) as described previously. In parallel, the cross-linker is 
attached to DLPE, giving rise to DLPE-MCC. Next, the two are combined together 
resulting in NP covered with lipid bilayer and malemide reactive groups. Lastly, 
cysteine modified CPP is attached to the construct by reacting with the malemide 
groups. 
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Figure 53. LipoNP-CPP fabrication: A) AgNPs are conjugated with DPTTE resulting in AgNP-DPTTE; 
B) in parallel SMCC is attached to DLPE; C) AgNP-DPTTE and DLPE-MCC are combined together into 
AgNP-DPTTE-DLPE-MCC; D) CPP-Cys is conjugated to AgNP-DPTTE-DLPE-MCC resulting in LipoNP-
CPP. 
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Second approach involved the use of polyethylene glycol in place of the lipid 
bilayers. PEG is inexpensive, water soluble, coiled polymer of repeating ethylene 
ether units, commonly used to functionalise the surface of nanoparticles. 
The molecule is known to improve particle stability and passivate the NP surface 
from unspecific physisorption when applied to biological samples. It has been also 
reported that PEG coating, known also as PEGylation, can enhance the particle 
transport through biological barriers. 169-172 
Thiol-PEG-amine (2000 Da) (Figure 54) was obtained and applied to the AgNP 
functionalisation, what also allowed the use of SMCC cross-linking chemistry for 
the CPP attachment.  
 
 
Figure 54. Thiol-PEG-amine. 
 
The protocol of the probe fabrication with the use of PEG was developed. 
Schematic representation of the process is shown in Figure 55 below. This 
procedure consists of three steps; Firstly, AgNPs are covered with PEG molecules 
using thiol-silver chemistry. Next, the cross-linker is attached to the PEG by reacting 
with PEG’s primary amines. This step is followed by the addition of CPP-Cys bonding 
to the construct by reacting with the malemide groups. 
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Figure 55. Fabrication of NP-PEG-CPP: A) AgNPs are covered by Thiol-PEG-Amine; B) MCC is 
attached to the free amine groups on the PEG coated particles; C) CPP-Cys is conjugated to AgNP-
PEG-MCC resulting in NP-PEG-CPP. 
4.5. Nanoprobe assessment 
To prove that the functionalisation of the nanoparticles with CPP-Cys was 
successful, the fabricated probes were next analysed by MALDI MS, DLS 
measurements and TEM imaging.  
 
The mass spectra of the Lipo-NP-CPP showed the presence of DLPE-CPP conjugates: 
m/z 3221 [M+H]+ and m/z 3265 [M+2Na]+. This was expected taking into account 
the non-covalent nature of DLPE-CPP complex attachment to the particle. During 
the ‘in-vacuum’ mass spectrometric experiment the complex easily detaches from 
the nanoprobes (Figure 56).   
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Figure 56. MALDI MS detection of  DLPE-CPP complexes (m/z 3221 [M+H]
+
 and m/z 3265 [M+2Na]
+
) 
on the fabricated Lipo-NP-CPP probe (A). No ions of bare silver nanoparticles, analysed as negative 
control,  were detected in the analysed mass range (B). 
 
 
In order to confirm the presence of CPP in the NP-PEG-CPP construct, by MALDI MS, 
the pre-treatment of the probe was necessary. In this case all the links between 
different nanoprobe modules were of covalent nature. Hence, it proved difficult to 
fragment the construct into informative molecular ions. Ammonium thiocyanate, 
known to react with silver resulting in its precipitation, was added to the solution of 
NP-PEG-CPP.  After 1 hour incubation the solution with dissolved silver particles and 
released PEG-CPP conjugates were analysed. Analysis of MALDI mass spectra 
revealed the presence of the PEG-CPP complexes: m/z 4805.8 [M+H]+ (Figure 57). 
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Figure 57. MALDI mass spectra of the detected PEG-CPP complexes (m/z 4805.8 [M+H]
+
)  from the 
fabricated and dissolved in ammonium thiocyanate NP-PEG--CPP probe (A). For comparison, 
spectra of intact NP-PEG-CPP probe (B) and bare AgNPs, where no ions were detected in the 
analysed mass range (C). 
 
 
The functionalised nanoprobes were then analysed by DLS. For comparison, 
bare 20nm AgNPs were also employed. As previously, the LipoNP-CPP were 
extruded through 50 nm pore size membrane prior to the DLS analysis. No 
particular change in the particle diameter was observed when LipoNP-CPP were 
measured. In addition, a presence of high molecular weight components was 
observed in the solution (Figure 58).  
The notable change in the diameter was observed for the NP-PEG-CPP 
complex. A fraction of aggregates within the sample was also observed, while 
calculating the size distribution by intensity. However, as indicated by volume and 
concentration records, monodisperse nanoprobes constituted the main population 
of particles in the sample (Figure 59).  
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Figure 58. DLS measurements showing the difference between bare AgNPs 20 nm (red trace) and 
lipo-NP-CPP (green trace). Particle size distributions are presented by intensity (top panel), volume 
(middle panel) and number (bottom panel). 
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Figure 59. DLS measurements showing the difference between bare AgNPs 20 nm (red trace) and 
NP-PEG-CPP particles (green trace). Top panel presents particle size distribution by intensity, 
middle by volume and bottom panel by number. 
 
Further assessment of the LipoNP-CPP and NP-PEG-CPP constructs was carried 
out by transmission electron microscopy (TEM). The method provides information 
of sample shape and morphology and enables imaging at high, sub-nanometer 
resolution (see 5.1.7).173, 174 For comparison, bare particles as well as particles with 
only CPP-Cys attached (NP-CPP) were also imaged.  
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Examination by TEM showed the lack of aggregation of the constructed 
NP-PEG-CPP (Figure 60, Figure 61 & Figure 62). However, no visual difference could 
be observed between the NP-PEG-CPP and NP-CPP and NP-PEG-CPP particles.  
In contrast, LipoNP-CPP samples revealed fibrillar structures decorated with 
nanoparticles (Figure 63). This explained the results obtained by the prior DLS 
measurement. Most likely, the fibres are a result of the interaction and co-folding of 
DLPE-MCC-CPP assemblies. AgNPs with conjugated DPTTE in a form of inverted 
micelles, from where the outer lipid layer was detached, are drawn to the fibres. 
The reports of similar peptide-lipid assemblies have been found in the literature.175 
It is believed that similar structures are created, not accidently, but as a result of 
different processes that are happening at molecular level. Nevertheless, this 
phenomenon eliminated the further use of the LipoNP-CPP for the studies of 
mammalian cell transfection as the fibre assembly causes nanoprobe 
decomposition.  However, the nanoprobe construct as well as the fibres are being 
investigated and its antimicrobial properties are being evaluated.  
 
     
Figure 60. TEM images of bare 20 nm AgNPs. 
 
     
Figure 61. TEM images of AgNP-CPP conjugates. 
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Figure 62. Images of NP-PEG-CPP. 
 
 
 (A)    
 (B)    
Figure 63. LipoNP-CPP imaged by TEM, revealing fibre like structures (A)) and magnification 
showing nanoparticles attached to the fibres (B)). 
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4.6. Nanoprobe use in biological samples  
Following the successful nanoparticle functionalisation, cell transfection with 
the NP-PEG-CPP was next carried out.  
 
In three parallel experiments, human dermal fibroblasts (HDFa) were incubated 
with bare AgNPs, NP-CPP and NP-PEG-CPP. All three types of the particles were 
used at the same AgNP concentration of 5 µg/mL for 3 and 6 hours. Bare particles 
as well as NP-CPP served as a comparison. Precipitation of large fraction of particles 
was observed after adding bare AgNPs to the incubation medium. Nothing similar 
was noticed in the case of the two remaining types of nanoprobes. After washing 
off the cells from the non-internalised particles, cells were fixed by treatment with 
gluteraldehyde, embedded in resin and, following resin block slicing, imaged by 
TEM.  The imaging revealed that all, the bare AgNPs as well as the functionalised 
NP-CPP and NP-PEG-CPP were taken up by the cellular cytoplasm. 
The representative images can be found in Figure 64 to Figure 69. From the 
obtained images it was not possible to state the amount of internalised particles. 
Also, as judged by visual observation, the different incubation times did not result in 
any difference in the NPs uptake.  
 
 
    
Figure 64. Representative TEM images of HDFa cells transfected with bare AgNPs after 3 h 
incubation. 
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Figure 65. Images of HDFa cells transfected with bare AgNPs after 6 h incubation. 
 
    
Figure 66. HDFa cells after 3 h incubation with NP-CPP. 
 
   
Figure 67. TEM of HDFa cells incubated with NP-CPP for 6 h. 
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Figure 68. Representative TEM images of HDFa cells transfected with NP-PEG-CPP after 3 h 
incubation. 
 
   
Figure 69. TEM images of HDFa cells transfected with NP-PEG-CPP after 6 h incubation. Beads-on-
string structures are clearly visible. 
 
Despite the lack of visible differences in terms of transfection efficiency 
between different particles, distinct structures, described for the purpose of this 
chapter as ‘beads-on-string’, were evident in the cells treated with NP-PEG-CPP 
(Figure 69, Figure 70). Similar structures could be observed in cell samples treated 
with gold nanoparticles, where osmium and lead staining was used (based on 
personal communication with Mark Turmaine, (UCL). The structures may present 
a fixation artefact. However, it is suspected that they are related to a protein or 
peptide material attached to the nanoparticles. There is also question arising from 
the fact, that those features were only observed when cells were incubated with 
PEG-coated probes and for longer time. Is this the functionalisation of 
the nanoprobes causing the cell to produce the ‘beads-on-string’, such as PEG-CPP 
assemblies, or is there a possibility of the probe interaction with specific molecules 
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within the cell? More studies are needed to investigate the findings and provide 
more information regarding content associated with the structures.  
 
    (A)    
 
   (B)     
Figure 70. TEM images of “beads-on-string’ like structures; lower (A) and higher (B) magnification. 
Those features were only observed in cells transfected with NP-PEG-CPP after 6 h incubation.  
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4.7. Conclusions 
In this chapter, generic, functionalised peptide nanoprobes were described. Silver 
nanoparticles served as a base for creation of modalities for intracellular delivery.   
Initially, metallic nanoparticles were coated to enable their surface-
passivation. Covering the particles by lipid bilayer prevented non-specific surface 
physisorption of biomolecules from a complex serum sample. Also, such prepared 
particles proved easy to handle and stable under vigorous treatments.  
Next, two protocols for the functionalisation of silver nanoparticles with 
a model cell penetrating peptide were developed. They included lipid bilayer and 
polyethylene glycol coatings, to which the CPP was cross-linked. The ability of 
the created probes to interact with the cells was investigated by transmission 
electron microscopy. 
 Examining of the created probes and their behaviour with the mammalian 
cells led to several conclusions:  
Firstly, images of LipoNP-CPP exposed the presence of fibre-like structures in 
the samples, which are most likely a result of the co-folding of DLPE-MCC-CPP 
molecules. This observation excluded the further use of the LipoNP-CPP for the 
studies in cell transfection experiments;  
Secondly, the transfection efficiency to HDFa cells of NP-PEG-CPP probes has 
been examined and compared to the uptake of bare AgNPs and peptide only-coated 
particles. Although no visible differences from the applications of the different 
particles have been observed, the NP-PEG-CPP proved well suited to 
the transfection purpose. Same time, distinct structures were discovered in the cells 
treated with NP-PEG-CPP. The nature of the structures is not known and requires 
further investigation.  
The use of metallic particles as the base for the intended nanoprobes enabled 
their clear visualisation in cell compartments. The particles are imaged by TEM 
without the need for any additional dyes of fluorescent ligands. It would not be 
possible if only cell penetrating peptides alone were employed to the intracellular 
delivery studies.    
At last, the employed nanoparticle surface coating appeared beneficial in 
comparison to the use of bare nanoparticles.  Once created, the nanoprobes are 
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stable and insusceptible to aggregation and precipitation in high-salt solutions, such 
as cell culture media.  
 
In summary, the attempt to functionalise nanoparticles with function-carrying 
model peptides was successful. In this study as a model system, a cell penetrating 
peptide was used, which directed the probes to the cell cytoplasm. The created 
platform forms a base for the fabrication of nanoprobes. In the future applications, 
nanoparticles can be readily conjugated with other peptidic moieties, targeting 
different organelles and with desired properties and specific activities, resulting in 
specific bio-molecular markers, intracellular cargo delivery or selective biomarker 
targeting and binding. 
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CONCLUSIONS AND OUTLOOK 
 
 
 
 
 
Peptides can serve as excellent biomarkers and can be also used as templates in 
chemical biology for the design of peptide-mediated probes. Advancements in 
nanotechnology provide opportunities to establish novel, sensitive, and selective 
methods for a wide range of bioanalytical platforms. This project investigated 
a specialist intra- and extracellular targeting, enabled by rationally designed 
membrane-active, as a base for the development peptide-based tools, for 
applications in cell biology, in a form of nanoscale probes. 
 De novo designed cell penetrating and antimicrobial peptides were assessed as 
candidates for a nanoprobe functionalisation to allow specific cell surface and trans-
membrane targeting. The interactions of the peptides with model bacterial and 
mammalian cell membranes were assessed using molecular biophysics and 
microbiology assays. The results confirmed that the peptides differentially interact 
with the two kinds. The peptides possess effective antibacterial properties while not 
exposing destructive effects towards mammalian membranes. 
The elucidation of the mechanism of the antimicrobial action was carried by 
new comparative approach, where atomic force microscopy analyses were 
combined with stable isotope imaging by Nano-Secondary Ion Mass Spectrometry. 
This provided high-resolution visualisation of the topography of peptide-treated 
membranes complemented by chemical imaging, revealing the precise localisation 
of peptide molecules in the membranes. The results allowed reviewing 
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the prevailing molecular model for antimicrobial mechanisms. It was shown that the 
formed pores are not limited to a particular diameter, nor they are transient, but 
can expand laterally at the nano-to-micrometer scale to the point of complete 
membrane disintegration. Real-time AFM imaging in liquid further confirmed 
the findings.  
Model cell penetrating peptides were used to investigate targeted 
intracellular delivery and endosomal release. Confocal fluorescence microscopy 
revealed different fluorescent patterns for two studied peptides: de novo 
engineered CPP and naturally occurring TaT. Differential accumulation of 
the peptides in Human Dermal Fibroblasts (HDFa) was observed.  CPP dispersed in 
the cytoplasm, while TaT remained entrapped within endosomes. These results 
confirmed that the de novo design of CPP promotes peptide escape to into 
the cytoplasm by permeabilising endosomal membranes.  
 In parallel, peptidomic processing approach was implemented and validated for 
the quantification of cellular uptake of the two cell penetrating peptides. 
The method presents tag-free approach and employs combination of liquid 
chromatography and isotope dilution MALDI mass spectrometry. The quantities of 
designed and naturally occurring peptides, internalised in HDFa were measured, 
compared against each other and correlated to the observations provided by 
fluorescence confocal microscopy. The applied methodology proved to be simple 
and reproducible and possessing several advantages over commonly used tag-based 
methods. The obtained results suggest that under applied experimental conditions, 
the engineered CPP is similarly efficient, in terms of cell penetration, as 
the endogenic TaT. This aids the concept of rational design and the use of synthetic 
biology for the development of novel tools. 
The last part of the research focused on the development of a generic 
nanoprobe with the use of metallic nanoparticles and cell penetration peptides. 
Preliminary results pointed to the need of the particle surface passivation against 
the undesirable, non-specific binding of molecules from biological samples. For 
these reasons, the protocol for the coating of silver nanoparticles with lipid bilayer 
was established and the coated particles were assessed, proving their stability, ease 
of recovery as well as their passiveness towards surface non-specific physisorption.  
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Two protocols for the functionalisation of nanoparticles were established. 
In the first approach, CPP was attached to the particle via modification to lipid 
bilayer, in which the particle was enclosed. The second method comprised 
the covering of the particles with PEG coating, followed by the conjugation of 
the peptide. The created nanoprobes were examined by transmission electron 
microscopy. Images of LipoNP-CPP reviled the presence of fibre-like structures in 
the samples, which are most likely a result of the co-folding of DLPE-MCC-CPP 
molecules. This observation excluded the further use of the LipoNP-CPP. However, 
the construct is now investigated under separate project run in Bioengineering 
Group at NPL, where its assembly process and antimicrobial properties are being 
evaluated. The proficiency of the second designed probe, NP-PEG-CPP was tested 
with living cells and compared to the effect that bare AgNPs and particles coated 
with the peptide only have on the cells. Despite the fact that no visible differences 
from the applications of the particle variants were observed, some distinct 
structures, which can be described as ‘beads-on-string’, were noticed in the cells 
treated with NP-PEG-CPP. No reported evidence of similar phenomena has been 
found and presently their origin can only be speculated. The nature of 
the structures is not known and requires further investigation by carefully designed 
studies, taking into account many factors such as nanoprobe functionalisation and 
its interaction with biomolecules within the cells, the cell response to the treatment 
with the probe or thorough examination of sample preparation process for TEM 
imaging and its effect on the probed material. Still, the attempt to functionalise 
nanoparticles with function-carrying ligands was effective.  
 
Research described in this thesis is complex and challenging. It resulted in several 
publications, reprints of which can be found in the following section. This research 
does not finish here and already several of its parts are investigated under follow-on 
projects. This research provides a base for the further use of rational peptide design 
for specific cell surface and trans-membrane targeting and intracellular delivery, 
and the fabrication of peptide-based tools in a form of multi-functionalised 
nanoprobes of desired properties and activities. 
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  CHAPTER 5
METHODOLOGY 
This chapter provides a brief overview of the main techniques employed in 
the course of the study, their short description and examples of relevant 
applications. Further, all methods used and detail protocols implemented to the 
described experiments are given.  
5.1. Techniques 
5.1.1 CD 
Circular dichroism (CD) is a spectroscopic technique that measures the difference in 
absorbance of right-hand and left-hand circularly polarised light by optically active 
samples. CD can be expressed by the following equation: 
CD = Absorption(right) - Absorption(left). Light absorbances in the ultraviolet (UV), 
visible and infrared (IR) wavelength regions are routinely used in chemical and 
biochemical research to probe secondary structure and conformational changes of 
molecules in solution. Therefore, CD has become a standard method in the 
characterisation of biopolymers such as peptides, proteins and nucleic acids.  
Far-UV CD is applied for the structural characterisation of peptides allowing 
estimating the degree of peptide conformational order and secondary structure 
content (e.g. α-helix). To the key points for visual assessment of secondary 
structure, based on CD spectrum, belong the following facts: a) α-helix results in 
negative bands at 222 nm and 208 nm and a positive band at 193 nm; b) β-sheet 
gives negative bands at 218 nm and positive bands at 195 nm and c) the lack of any 
ordered secondary structure will not present any peaks above 210 nm. Exemplar CD 
spectra  associated with various types of secondary structures can be found in 
Figure 71. 140 
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Figure 71. Far UV CD spectra associated with various types of secondary structure. Solid line, α-
helix; long dashed line, anti-parallel β-sheet; dotted line, type I β-turn; cross dashed line, extended 
31-helix or poly (Pro) II helix; short dashed line, irregular structure. Reprinted from Kelly, et al., 
Biochim Biophys Acta, 2005.
140 Copyright © 2005, with permission from Elsevier. 
 
5.1.2 LD 
Linear dichroism (LD) is related to the CD technique as both methods are based on 
the difference between the absorbances of differently polarised light beams. 
However, LD measurements are based on the differential absorption of linearly 
polarised light and are informative only when performed on systems that are or 
intrinsically oriented or can be oriented during the experiment. The difference in 
absorption of light linearly polarised parallel and perpendicular to the orientation 
axis is measured. Therefore, LD can be expressed by the following equation: 
LD = Absorption(parallel) – Absorption(perpendicular). LD measurements are illustrated by 
Figure 72. 
LD is an extremely attractive technique, which allows working in solution 
phase, providing information about conformation and orientation of sub-units of 
biomaterials and orientations of the whole biomaterial with respect to 
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an orientation axis. It can be used to study various samples such as: DNA, DNA-
ligand complexes, carbon nanotubes, peptide and protein fibers. It can give insight 
into interactions between membrane proteins and peptides with liposomes. When 
the secondary structure of the probed molecule, such as peptide, is known (e.g. 
α-helical or β-sheet), it allows its orientation to be approximately determined. 
Figure 73 shows expected LD signals for an α-helix and a β-sheet species lying flat 
on the surface or being inserted in a membrane. 
 
 
 
Figure 72. Schematic illustration of an LD experiment. Reprinted from Bulheller, et al., Phys Chem 
Chem Phys, 2007
176
 with permission of the PCCP Owner Societies. 
 
 
 
 
Figure 73. Scheme of expected LD signals; (a) an α-helix on or in a membrane, and (b) a β-sheet 
lying flat on the surface of or in a membrane. Reprinted from Hicks, et al., Chem Soc Rev, 2010
143
 
with permission from the Royal Society of Chemistry. 
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5.1.3 AFM 
Atomic force microscopy (AFM) is a powerful surface analytical technique, which 
works by scanning a sample with a sharp, usually silicon tip, mounted at the end of 
a flexible cantilever. The AFM can image in a number of ways of which two most 
popular are: contact mode or an oscillating mode where the tip taps the surface. 
The forces between the tip and the sample during scanning cause the cantilever to 
deflect. Typically, the deflection is monitored using a laser beam and photodiode 
(Figure 74).   
AFM allows generating high-resolution topographic surface images, with 
a spatial resolution down to 1-20 nm, depending on the sharpness of the used tip. It 
can be used to probe samples in air, in liquid or in vacuum. Apart from 
the topography, AMF can also provide some information on nanoscale chemical, 
mechanical, electrical and magnetic properties of the probed surface. AFM is 
commonly used in biology to study nucleic acids, proteins and peptides, tissues and 
living cells. The possibility to perform such measurements in situ is, next to the high-
resolution the main advantage of this technique. 
An example of AFM application is given below, represented by images 
obtained from the observations of the effects poly(amido amine) dendrimers have 
on  supported 1,2-dimyristoyl-sn-glycero-3-phosphocholine  (DMPC)  bilayers 
(Figure 74).177  
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Figure 74. Diagram of an AFM: (a) AFM images surfaces or measures forces by scanning a tiny tip 
mounted at the end of the cantilever on a sample, which is controlled by a piezoelectric scanner. 
Interactions between samples and the tip are recorded by laser that is reflected to a split 
photodetector; (b)-(d) Example of AFM imaging of supported DMPC lipid bilayer after interaction 
with poly(amido amine) dendrimers. White lines highlight some of the areas where dendrimers 
have affected the bilayer (the dendrimer themselves cannot be seen on the images). (b) 
dendrimers cause the formation of small holes, 15–40 nm in diameter, in the previously intact 
parts of the bilayer; (c) dendinmers remove lipid molecules primarily from edges of existing bilayer 
defects; (d) Neutral in charge dendimers do not remove lipid molecules from the surface. Instead 
they adsorb to edges of existing bilayer defects. Reprinted with permission from Jin, et. al,  
Microsc Res Tech, 2010.
177
 Copyright © 2010 Wiley-Liss, Inc. 
 
5.1.4 NanoSIMS 
Secondary ion mass spectrometry (SIMS) is a highly sensitive analytical technique 
for investigations of sample surface chemistry, being able to detect elements 
present in parts per billion ranges. 
In SIMS, the surface is bombarded by charged primary ion beam in vacuum 
what effects in sputtering (desorption) of the top few atomic layers, and ejection of 
atoms, ions and clusters (Figure 75). The resulting secondary ions are collected and 
mass analysed. The great information content of this technique leads to 
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unambiguous identification of molecules by their mass and to visualisation of 
the distribution of the molecules in the sample. Images are obtained by scanning 
the primary ion beam across the sample and collecting a spectrum at each spot. 
SIMS, and in particular NanoSIMS, which gives the most precise molecular content 
of the surface in question, with spatial resolution down to 50 nm, allows to identify 
isotopic composition of the probed sample, which can be translated into chemical 
details.   
The capability of detail analysis and powerful sensitivity of this method in 
biological research can be exemplified by the application of NanoSIMS to 
the detection and visualisation of  trace  amounts  of  selenium  in  wheat  grains 
(Figure 76).178 
 
 
 
 
Figure 75. Cartoon presenting sputtering process in SIMS experiment. Image adapted from 
http://www.eaglabs.com/training/tutorials/sims_theory_tutorial/index.php. 
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Figure 76. Example of NanoSIMS imaging; NanoSIMS ion maps of the outer part of the wheat grain 
showing the distribution of 16O−, 12C14N−, 32S−, 31P16O−, 80Se− and secondary electron (SE) signals. 
Reprinted with permission from K. L. Moore et al., New Phytol., (185), 2010.
178
 Copyright © 2009 
The Authors & Journal compilation New Phytologist. 
 
5.1.5 MALDI MS 
MALDI is a soft ionisation technique used in mass spectrometry allowing the 
analysis and of a wide range of organic and inorganic molecules. In MALDI MS 
a matrix compound, usually a small organic acid, is applied to the sample surface, 
where co-crystallisation of the sample with the matrix takes place. Ionisation of 
analytes occurs when the dried matrix is irradiated with a focused laser beam. 
The energy from the laser is absorbed by the matrix, resulting in a rapid desorption 
of the molecules from the radiated spot. A mass spectrum of the ions is then 
recorded. 
MALDI MS has become an invaluable tool in life sciences, allowing accurate 
and sensitive analyses of various samples including: proteins and peptides, lipids, 
drugs and metabolites, carbohydrates, nucleic acids, synthetic polymers and large 
organic compounds. A great advantage of mass spectrometry is that multiple 
analytes can be monitored simultaneously from a single sample, without prior 
knowledge of their identities. Also in principle, there is no requirement for the use 
of target-specific reagents such as chemical tags, antibodies or large dye labels. 
Therefore, the insights into biological processes are provided with little or no 
disturbance of the native content of molecules in the samples. 
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5.1.6 DLS 
Dynamic light scattering (DLS), also referred to as photon correlation spectroscopy, 
is a robust technique, which can be used to measure the size as well as the size 
distribution of particles held in suspension. The measurements are based on 
the time-dependent fluctuation in the light scattering intensity caused by Brownian 
motion (random, constant change in the distance) of molecules in the solution. 
When the laser beam, travelling through the sample to the detector, meets 
the particles in the sample, scattering of the light beam occurs. Larger particles will 
cause more scattering then the smaller ones. However the smaller molecules will 
result in greater change in scattering over a given time period as they will move 
quicker.   Analysis of the fluctuation of the light intensity, hitting the detector, yields 
the information on the size of the particles. The changes of the scattered light are 
converted into electrical pulses, which are next fed into a digital correlator. 
Autocorrelation function is generated, from which appropriate data analyses are 
performed. The measurements are dependent on the concentration of molecules in 
the sample, the size of the particle core as well as the size of surface structures, and 
the type of ions in the suspension medium. In monodisperse systems, containing 
one particle population, the mean diameter of the particles can be effectively 
determined.  Polydisperese systems would show multiple particle populations. 
DLS can be utilised to characterisation of various particles including peptides, 
proteins, micelles, polymers, carbohydrates, etc. In particular, it has become 
an invaluable tool for sizing nanoparticles. The example of the use of DLS to 
the characterisation of engineered gold nanoparticles (GNPs) has been given by 
Pandey and co-workers179, who constructed antibody-conjugated nanobioprobe for 
the detection of typhoid fever. The DLS measurements show clear change in 
the particle size as the result of modification to the particle surface. 
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Figure 77. TEM images of colloidal gold particles (A) and GNPs–antibody conjugates (B). DLS 
(dynamic light scattering) data of GNPs and GNPs–antibody conjugate (C). Adapted with 
modifications from Pandey, et al.,  Mol Biosys, 2012
179
 with permission from the Royal Society of 
Chemistry. 
 
5.1.7 TEM 
Transmission electron microscopy (TEM) uses a beam of electrons to create 
an image of the probed sample. It has much greater resolving power and is capable 
of considerably higher magnifications than a light microscope, what allows imaging 
smaller objects in finer detail, down to nanometer scale. The imaging method 
involves illumination a sample, in high vacuum, with high voltage electron beam and 
next detecting, the electrons transmitted through the sample. TEM enables 
obtaining two-dimensional, black and white “images”.  
The preparation of a biological sample, such as cells or tissue to be viewed in 
an electron microscope, usually requires several stages, some of which are quite 
complicated and critical. It is mainly due to the analyses being held in high-vacuum. 
There are many approaches involved in the process, which will depend on the type 
of the sample, origin of the sample as well as the size of the specimens of interest. 
Firstly, sample has to be preserved, which can be done by, for example, cryofixation 
in liquid nitrogen or chemical fixation such as treatment with glutaraldehyde, used 
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to crosslink protein molecules and osmium tetroxide to preserve lipids. Also 
dehydration of the sample is required and the water is usually replaced with organic 
solvents like ethanol or acetone. Often embedding of the sample in a resin, such as 
LR White is carried out, which then is polymerised into a hardened block for 
subsequent sectioning. To give contrast between different structures, staining with 
heavy metals, e.g. uranium and lead, can be also employed. Finally, to prevent 
charging of the specimen that can result from the irridation by electron beam, 
sputter coating of the sample with electrically-conducting material, such as 
platinum, gold or chromium is applied. 
TEM has proven to be an invaluable tool for analysis of various organic and 
inorganic structures. It allows, with a great detail, probing cell architecture.  By 
visualisation and localisation of cell structures it enables their identification and 
brings insight into related to them functions. Therefore, TEM gained significant 
popularity in the fields of cell and tissue biology and became very useful in 
biomedical research. Since successful imaging of nanomaterials, including 
nanoparticles, can be too carried out, TEM imaging is also extremely attractive in 
the area of bio-nano research and applications.  An example of the TEM imaging is 
given in Figure 78, which pictures internalisation by and distribution within of 
engineered nanoparticles particles by human glioma cells. 180 
 
 
Figure 78. TEM images showing internalisation of mesoporous silica protected gold nanoclusters 
by 42-MG-BA human glioma cells. (a) Arrows indicate the intracellular distribution of nanoparticles 
in endosomes, which show variable size and particle number. (b) Large aggregates of nanoparticles 
could be related with some deficient dispersion in cell culture medium. Although nanoparticles 
localised frequently close to the nucleus they do not appear to enter. Reprinted from Botella, et 
al.,  Dalton T, 2012
180
 with permission of the Royal Society of Chemistry. 
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5.2. Materials and methods 
5.2.1 Materials and reagents 
LC-MS grade water, α- cyano-4-hydroxy-cinnamic acid (ACCA), 2,5-dihydroxybenzoic 
acid (DHB), sinapinic acid (SA), succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-
carboxylate (SMCC) and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (sulfo-SMCC) and serum were purchased from Sigma; Silver 
nanoparticles (AgNPs) 10 nm and 20 nm (1 mg/ml stock) in the form of BioPure 
silver, were obtained from nanoComposix, USA. Lipids: 1,2-dipalmiotyl-sn-glycero-3-
phosphotioethanol (DPPTE) and  1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 
1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) and 1,2-dilauroyl-sn-
glycero-3-phospho- (1’-rac-glycerol) (DLPG) were obtained from Avanti, USA; and  
thiol-PEG-amine from NanoCS, USA. Peptide Calibration Standard as well as Protein 
II Standard Mix from Bruker; Human Dermal Fibroblasts (HDFa) (ATCC number PCS-
201-012,), were taken from in-house stock (Bioengineering, NPL, UK); Cell culture 
media OptiMem Reduced Serum Medium and M106 were obtained from Gibco. 
Other used reagents used were from ‘in-house’ stock (Bioengineering, NPL, UK) and 
included: phosphate buffer, phosphate buffered saline (PBS), citrate buffer, 
glutaraldehyde, chloroform, acetonitrile, methanol, diisopropylethylamine (DIPEA); 
tris(2-carboxyethyl)phosphine (TCEP). 
5.2.2 Peptides 
The following peptides: AMP (sequence: KQKLAKLKAKLQKLKQKLAKL -am), non-AMP 
control (sequence QIAALEQEIAALEQEIAALQ-am) and CPP (sequence: 
KIAKLKAKIQKLKQKIAKLK-am) were de novo designed by Dr Maxim Ryadnov 
(Bioengineering, NPL, UK). 
 
All peptides: AMP, non-AMP control, CPP, CPP-H (containing Leu 6C131N15 at 
residue 19), CPP-Cys (sequence: CKIAKLKAKIQKLKQKIAKLK-am), TaT (sequence: 
YGRKKRRQRRR-am) were chemically synthesised using a solid-phase peptide 
synthesis181, either by Dr Angelo Bella or Dr Lloyd Ryan (Bioengineering, NPL, UK) 
15N-AMP, (labelled at all alanine and leucine residues) and TaT-H were purchased 
from AnaSpec, USA. AMP-F (containing Trifluoroethylglycine (TfeGly) at position 4) 
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was synthesised and provided in kind by Dr Ulla Gerling and Prof. Beate Koksch 
(Institut für Chemie und Biochemie, Freie Universität Berlin, Germany).  
 
Peptides produced ‘in house’ were purified by semi preparative reversed-phase 
high performance liquid chromatography (RP-HPLC) on Jasco preparative liquid 
chromatography system. Purities of all peptides were checked by analytical RP-HPLC 
(analytical Jasco system) and MALDI-ToF mass-spectrometry (Autoflex III, Bruker). 
 
Peptide concentration determination: Peptide concentrations were determined by 
converting UV absorbance measured at 214 nm, on Lambda 850 Spectrometer, 
using 1 cm path length quartz cuvette. The concentration was estimated based on 
the composition of amino acids, using calculated extinction coefficients182: Ɛ214 
[M-1cm-1]: 19621 (AMP, AMP-H and 15N-AMP), 18556 (CPP and CPP-H), 18879 (non-
AMP), 19704 (CPP-Cys) and 15462 (TaT).  
5.2.3 Methodology  
Preparation of liposomes: Liposomes of the following composition were used: 75% 
DLPC (Figure 79) and 25% 1,2-dilauroyl-sn-glycero-3-phospho- (1’-rac-glycerol) 
(DLPG) (Figure 80) (w:w). Firstly, the lipids were weighted up and dissolved of a 
solution consisting of CHCl3 and CH3OH (3:1 (v:v) respectively). The lipid solution 
was blow-dried under air stream and exposed, overnight, to vacuum. After, the 
dehydrated lipids were reconstituted in LC-MS grade water and ultrasonicated. To 
create small unilamellar vesicles (SUV), the obtained solution was extruded fifteen 
times through 50 nm-pore membrane (Waters). 
 
Figure 79. Chemical structure of DLPC. 
 
 
Figure 80. Chemical structure of DLPG. 
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Circular dichroism spectroscopy (CD): All CD spectra were recorded on a JASCO J-
810 spectropolarimeter. The measurements were taken in ellipticities in mdeg and 
converted to molar ellipticities ([θ], deg cm2 dmol-1) by normalising for the 
concentration of peptide bonds. Aqueous peptide solutions (300 μL, 20 μM) were 
prepared in filtered (0.22 μm) 10 mM phosphate buffer, pH 7.4. CD spectra 
recorded in the presence of synthetic membranes are for lipid:peptide molar ratio 
of 100:1. 
 
Linear dichroism spectroscopy (LD): The analyses were performed with assistance 
of Dr Jascindra Ravi (Bioengineering, NPL, UK). Solution-phase flow linear dichroism 
spectroscopy was performed on a Jasco-810 spectropolarimeter using a photo 
elastic modulator 1/2 wave plate, and a micro-volume quartz couvette flow cell 
with ~0.25 mm annular gap and quartz capillaries (Kromatec Ltd, UK). Molecular 
alignment was achieved through the constant flow of the sample solution between 
two coaxial cylinders – a stationary quartz rod and a rotating cylindrical capillary. LD 
spectra were acquired with laminar flow obtained by maintaining the rotation 
speed at 3000 rpm and processed by subtracting non-rotating baseline spectra. LD 
spectra recorded in the presence of synthetic membranes, DLPC and DLPC:DLPG 
(3:1), were prepared at a lipid:peptide molar ratio of 100:1 (2 mM total lipid, 20 μM 
peptide). 
 
Stain-Dead Antimicrobial Assay. E. coli culture (1 mL) was centrifuged to give a cell 
pellet, which was washed twice with PBS (pH 7.4) before being reconstituted in PBS 
to give OD600nm = 0.008. One millilitre of the solution was dispensed in a two-well 
glass chamber (LabTek) with diluted (1/500) propidium iodide (PI) (1 mg/mL; 
Invitrogen). The chambers with surface-settled bacteria (60 min) were mounted on 
a confocal microscope (Olympus) equipped with an incubation chamber at 37 °C. PI 
fluorescence emission was monitored at 625 nm for 60 min (3 frames/min) using an 
appropriate filter after the addition of peptide (1 mL). Recorded movies (XYZ) were 
analysed using Fidji software to plot the number of fluorescent (stain-dead) cells as 
a function of time. Confocal microscopy analyses were performed by Mr Baptiste 
Lamarre (Bioengineering, NPL, UK). 
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Sample preparation for imaging: Oxidised silicon substrates (University Wafer, USA) 
were soaked in the previously described SUV solution and gently shaken for about 2 
hours to enable the deposition of the lipid bilayer on the surface. The excess of 
vesicles was removed by plunging the substrates, covered with the bilayer, into 
fresh water and gently shaking for several minutes (repeated 2 times). The created 
supported lipid bilayer was then treated with the peptide solution. Following 30-
min incubation and washing off the excess of the peptide, the samples were flash-
frozen in liquid nitrogen and freeze-dried. This process allowed the removal of 
undesired water, and also ‘fixed’ the changed bilayer composition. Three types of 
samples were analysed: a) silicon substrate, b) silicon substrate covered with lipid 
bilayer; and c) lipid bilayer on the silicon substrate treated with peptides. Bacterial 
cells were imaged directly following peptide treatment and washing. 
 
AFM imaging: The imaging was performed by Dr Santanu Ray (Surface & 
Nanoanalysis, NPL, UK). Topographic, amplitude and phase AFM images were 
recorded using tapping mode AFM on a MFP-3D Asylum AFM instrument (for 
imaging bacteria) and Cypher Instrument (Asylum Research, UK) for imaging 
supported lipid bilayers. All AFM images were flattened with a first order line-wise 
correction fit. AFM tips used were super-sharp silicon probes (Nanosensors, 
Switzerland, resonant frequency ~330 kHz, tip radius of curvature <5 nm, force 
constant 42 N/m). Images were processed using proprietary SPIP software, version 
5.1.3. 
 
NanoSIMS imaging: The NanoSIMS analyses were performed by Mr Haibo Jiang and 
Prof. Chris Grovenor (Materials Dept., University of Oxford, UK). SIMS images of 
chemical and isotopic distributions were acquired on a CAMECA (Gennevilliers) 
NanoSIMS 50 with lateral resolution down to 50 nm. The instrument uses a 16 keV 
primary 133Cs+ beam to bombard the sample surface and collects five selected 
secondary negative ions using a Mauttach-Herzog mass analyzer with electrostatic 
sector and asymmetric magnet configuration. 12C14N- and 12C15N- secondary ions 
were collected. Three of the following signals were also recorded simultaneously to 
give information on sample morphology; 12C-, 13C-, 16O- and 31P- . The ratio images 
(12C15N-/12C14N-) (30 by 30 μm, 256 by 256 pixels) were collected with a large 
primary aperture to match the pixel size in the images with the incident ion beam 
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diameter (~120 nm). A smaller primary aperture was used to achieve higher lateral 
resolution images (10 by 10 μm). The data was collected without preliminary 133Cs+ 
implantation to avoid sputtering away the thin samples23. The images were 
calculated and processed using OpenMIMS software (MIMS, Harvard University, 
www.nrims.harvard.edu/), were multiplied by a scale factor 10,000, and processed 
by a median filter with one pixel radius. Ratios of the control samples were 
calculated as: ratio = 12C15N- / (12C14N-+12C15N-) x 100%.  
 
Preparation of supported lipid bilayers for AFM in water: Performed by Ms Alice 
Pyne (LCN, UCL, UK). Supported lipid bilayers were formed on mica as described 
previously183 from a solution of 1.5 mg/mL DLPC:DLPG (3:1) in 150 mM NaCl, 20 mM 
HEPES pH 7.4 buffer with 20 mM MgCl2 and 20mM CaCl2. After absorption, the 
solution was then washed three 4 times with buffer, to remove the unfused vesicles 
from solution. Peptides were introduced in to the 100 µL fluid cell (JPK, Germany) at 
final concentration of 0.5 µM. 
 
Liquid AFM imaging: The imaging was performed by Ms Alice Pyne and Dr Bart 
Hoogenboom (LCN, UCL, UK). Topographic images of supported lipid bilayers in 
liquid were recorded on a JPK Nanowizard I AFM, mounted on an Olympus IX71 
inverted optical microscope, and operated in contact mode. The AFM probes used 
for all experiments in liquid were MSNL Silicon Nitride probes with spring constants 
of 0.005-0.03 N/m (Bruker AFM probes, CA, USA). Images were processed using 
Gwyddion (http://gwyddion.net/) for plane fitting and cross-section measurements. 
Confocal fluorescence microscopy analyses were performed by Mr Baptiste 
Lamarre (Bioengineering, NPL, UK) using Olympus IX81 confocal microscope at 
488 nm and using an x60 objective with appropriate filter. Images were processed 
using Imaris v5.1 and Image J software. 
 
Cell transfection for quantification: Human Dermal Fibroblasts (HDFa) (ATCC 
number PCS-201-012,), from stock stored in in liquid nitrogen (NPL), were thawed 
and next seeded in 25cm2 flasks with 10 mL of complete M106 media (Gibco) and 
antibiotics (gentamicin and amphotericin B). Cells incubated at 37°C, 5% CO2 until 
at least 80% coffluency achieved. Next, media were removed and replaced with 
10 mL of 10 µM peptide (CPP or TaT) in OptiMem Reduced Serum Medium (Gibco).  
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After 3 h of incubation at 37°C, 5% CO2, the solution with the excess (non-
internalised) peptide was removed. To detach form the surface and to destroy any 
possible remaining on cell membranes peptide residues the cells were subjected to 
7 min treatment by Trypsin. After spinning down the cells for 5 min at 150 rpm 
supernatant was discarded and cell pellet re-suspended in 1 mL of PBS pH7.4. 20 µL 
of the solution was next mixed with equal amount Trypan Blue (Fluka) and cells 
were counted using hematocytometer (Bright-Line) and optical microscope (Leica).  
The number of cells from at 5 squares were average, based on what the total 
amount of cells in the remaining solution was calculated. 
 
Cell transfection for fluorescence studies: Human dermal fibroblasts were seeded 
in 4-well plates (104 cells per well) and were grown in serum-supplemented M106 
for 2 days under the controlled environmental conditions. Cells were washed in a 
serum-reduced Opti-Mem medium and were transfected with 10 M peptide 
(0.2 mL per well). Fluorescence was visualised at different time points (1, 3, 8 and 
24 hours) by an Olympus IX81 confocal microscope at 488 nm using x10 and x20 
objectives with an appropriate filter. Life cell imaging was performed under the 
controlled environmental conditions. Images were processed using Imaris v5.1 and 
ImageJ software. Transfection efficiency was calculated by dividing total 
fluorescence by the total number of cells. The highest value for each peptide (8-
hour incubations) was taken as 100% after the subtraction of background 
fluorescence. Statistical analysis was performed by OriginPro 8.5 using ANOVA 
followed by a Fisher post-test for three independent experiments done in triplicate. 
The analyses were performed by Mr Baptiste Lamarre (Bioengineering, NPL, UK). 
 
Cell lysis in Triton X: The counted cells suspension was divided in to two. Half of the 
solution was next spun-down (5min at 150 rpm) and re-suspended in lysis solution: 
0.1 % Triton X and 0.075 % TFA. Next the solution was subjected to four times 
freezing and thawing cycles and further incubation for few hours at room 
temperature, with several sonication and mixing steps in the meantime. Finally, the 
debris pellet was spun down and the supernatant containing cell lysate collected, 
freeze – dried and re-constituted in LC-MS grade water to volume of 500 µL. For 
the control, human dermal fibroblasts, which do not contain the CPP, were also 
lysated. 
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Cell lysis in Rapigest: Half of the solution of counted cells was spun-down (5min at 
150 rpm) and to the 100 uL of 50 mM NH4HCO3 buffer containing: 0.5 % (w/v) 
Rapigest Extraction Buffer (Waters), Protease Inhibitor Cocktail (Roche) and 2 µg / 
mL DNAse II (Sigma) was added. Three cycles of vigorous mixing and sonicating 
were applied and after 30 min DNA in the form of slimy threads was removed from 
the sample. Then two freeze-thaw cycles in liquid nitrogen were performed and the 
debris was removed by ultracentrifugation for 10 min at 14000 rpm. Clear 
supernatant was collected and diluted to volume of 500 µL. For the control, human 
dermal fibroblasts, which do not contain the CPP, were also lysated. 
 
Size Exclusion Chromatography (SEC): SEC was performed on Jasco analytical LC 
system equipped in multi-wavelength detector MD-2010 Plus; The column used was 
BioSep-SEC-s200, 300 x 7.8 mm (Phenomenex); The following run conditions were 
set: mobile phase: PBS, pH 7.4; Isocratic flow rate at 1 ml/min; Room temperature; 
Detection: UV absorbance at 214 nm. Sample amounts: 50 µg of pure solutions of 
CPP, CPP-H, TaT, TaT-H and molecular weight standards, 100 µL of cell lysates. 
The column performance was evaluated by injecting several molecular weight 
standards: BSA (66 kDa), Ferritin (450 kDa), Lysozyme (14 kDa), Ovalbumin (45 kDa) 
and Conalbumin (76 kDa). Next, the pure solutions of CPP, CPP-H, TaT and TaT-H 
were injected onto the column and their elution time was estimated. Fractions 
collected, freeze dried and reconstituted in 200 µL of LC-MS grade H2O.    
 
Reversed-phase HPLC (RP-HPLC): For MALDI MS quantification: RP-HPLC was 
performed on Jasco analytical liquid chromatography system; The column used was 
Vydac 218TP C18 5µ, 250 x 4.6 mm (Grace); The following run conditions were set: 
Mobile phase A: 5% Acetonitrile (ACN) in 0,1% Trifluoroacetic acid (TFA), Mobile 
phase B: 95% ACN in 0.1% TFA; Gradient: 95% A for 10 min, B  80% in 40 min, 80% 
B for 5 min, B  5% in 5 min, 95% A for 5 min, Flow rate at 1 ml/min; Room 
temperature; Detection: UV absorbance at 214 nm, Sample amounts: 50 µg of pure 
solutions of CPP, CPP-H, TaT and TaT-H and 100 µL of reconstituted SEC fractions. 
Fractions corresponding to the CPP elution time were collected for further analysis 
by MALDI MS.   
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MALDI MS of peptides was performed on Autoflex III (Bruker) Smart Beam, 
equipped with a nitrogen laser (337 nm, 200 Hz maximum firing rate), in positive 
polarity mode. The target plate used was AnchorChip 800 µm (Bruker) and 
the MALDI MS matrix was α- cyano-4-hydroxy-cinnamic acid (ACCA) (Sigma). 
The reflector detection mode was used to analyse CPP, CPP-H and respective to 
them samples. Linear detection mode was used to analyse TaT and TaT-H samples. 
The instrument was calibrated using Peptide Standard Mix (Bruker). 
 
Isotope dilution standard curves: Stock solutions of known concentrations of CPP 
and CPP-H were prepared. The concentration of the peptides was determined using 
UV absorbance at 214 nm. A set of solutions was prepared from the peptides’ stock 
solutions, with the amount of CPP ranging from: 0.5 pmol/µL to 5 pmol/µL and the 
CPP-H at the final concentrations at 1 pmol/µL. All the samples were next mixed 
with ACCA matrix in 1:1 ratio and deposited onto MALDI target plate in duplicates. 
To achieve good quality signal, for each sample spectra from at least 2000 laser 
shots and different positions on the sample spot were summed. Standard curves 
was built, which plots the ratio of the intensity of the CPP ion to the CPP-H ion 
intensity against the concentration of the CPP (Figure 81). The same procedure was 
employed to build up the standard curve for the quantification of TaT peptide 
(Figure 82). 
 
Figure 81. Standard curve showing the relation between the ratio of CPP and CPP-H ion intensities 
against concentration of CPP. The CPP-H was kept at the concentration of 1 pmol/µL while the 
concentration of CPP varied from 0.5 pmol/µL to 5 pmol/µL.   
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Figure 82. Standard curve of the relation between the ratio of TaT and TaT-H ion intensities against 
concentration of TaT. The TaT-H was kept at the concentration of 1 pmol/µL while the 
concentration of TaT varied from 0.5 to 5 pmol/µL.   
 
Preparation of lipoNPs: 6 mg of DPPTE (Figure 83) was dissolved in 2 ml chloroform. 
To 340 L of this solution 60 L 20 nm AgNPs was added. The sample was next 
sonicated for 30 min with occasional vigorous mixing. Next the sample was spun 
down (30 min at 10k rpm) and the supernatant removed. To remove DPTTE excess 
the NP pellet was three times with chloroform. 6 mg of DLPC was suspended in 2 ml 
of water. 500 µL of this solution was next added to the tube with the AgNP-DPPTE 
pellet and the sample was next sonicated for 1 h with occasional vigorous mixing. 
The remaining drop of chloroform was next extracted from the bottom of the tube 
and the sample was spun down (30 min at 10k rpm) and washed 3 times with water 
to remove excess DLPC vesicles. Schematic representation of the process is shown 
in Figure 84 below. To make sure that the created construct does not contain 
agglomerates, the lipo-AgNPs were extruded through a membrane of 50 nm pore 
size. 
 
Figure 83. Chemical structure of DPPTE. 
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Figure 84. Schematic representation of lipo-AgNPs preparation: A) AgNPs, kept in aqueous 
solution, upon mixing with DPPTE dissolved in chloroform, move to the organic phase; B) AgNPs 
covered by DPTTE are separated by centrifugation and washed several times with chloroform to 
remove excess lipid; C) Ag-NPs – DPPTE conjugates, kept in chloroform, upon mixing with DLPC 
suspended in aqueous solution, move to the aqueous phase; D) The AgNPs, covered with lipid 
bilayer, are separated by centrifugation and washed several times to remove excess lipid.  
 
Incubation of lipoNPs with serum: 10 µL of concentrated AgNPs and lipo-NP 
solutions were incubated with 500 µL of serum for 2 h at room temperature. 
The nanoparticles as well as the lipo-NPs were next separated from the serum by 
ultracentrifugation (30 min at 10k rpm) and subsequent washing with water 
(repeated four times). 
 
MADLI MS analyses of nanoparticles: The reflector detection mode was used; 
the samples were placed on the AnchorChip 800 µm target plate together with 
the MALDI matrix: DHB for the probing of lipo-AgNPs. SA matrix was used and linear 
detection mode for the analysis in higher molecular weight range to probe serum-
incubated samples. The instrument was calibrated using Peptide Standard Mix or 
Protein II Standard Mix. 
 
DLS measurements were performed on a Zetasizer Nano (Malvern Instruments, UK) 
and carried out in a low volume disposable cuvette at 25°C. Hydrodynamic radii 
were obtained through the fitting of autocorrelation data using the manufacture’s 
software, Dispersion Technology Software (DTS version 5.10). 
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Preparation of LipoNP-CPP: 6 mg of DPPTE was dissolved in 2 ml chloroform. 
To 340 L of this solution 60 L 20 nm AgNPs was added. The sample was next 
sonicated for 30 min with occasional vigorous mixing. Next the sample was spun 
down (30 min at 10k rpm) and the supernatant removed. To remove DPTTE excess 
the NP pellet was washed three times with chloroform. 25 mg of DLPE (Figure 85) 
was solubilised in 1 mL of CHCl3/CH3OH 9:1 (v:v). To this solution 7.5 µL of DIPEA 
and 14 mg of SMCC were added. Using indicator paper pH of the solution was 
checked (optimal pH 7.4) and the reaction solution was incubated with gentle 
shaking at room temperature. After 2 hours, to obtain dry crude of the DLPE-MCC 
conjugate the solution was dried under nitrogen flow. DLPE-MCC conjugate was 
next resuspended in 500 µL of CHCl3/CH3OH 9:1 (v:v) 100 µL of this solution was 
next added to the tube with the AgNP-DPPTE pellet, followed by addition of 500 µL 
H2O, and the sample was next sonicated for 30 min with occasional vigorous mixing. 
The sample was spun down (30 min at 10k rpm) and the aqueous phase, containing 
AgNP-DPTTE-DLPE-MCC construct was removed from the tube and placed in a fresh 
tube.  To the remaining DPPTE-NPs pellet another 100 L of DLPE-MCC solution and 
500 µL of H20 were added and the sonication and spinning process repeated. 
The obtained additional AgNP-DPTTE-DLPE-MCC construct was separated and 
pooled with the previously collected one. The sample was mixed vigorously and 
spun down (30 min at 10k rpm). After discarding the supernatant, 500 µL of fresh 
water was added and the sample was sonicated for 15 minutes until the solution 
gained clarity. The spinning down of the sample was repeated and after water 
removal the concentration of the silver particles in the remaining solution was 
determined (as described further). 500 µL of CPP-Cys solution in 10 mM phospahe 
buffer and 1 mM T-CEP was added to the remaining AgNP-DPTTE-DLPE-MCC pellet 
in 1.1:1 molar ratio and the reaction was allowed for 3 hours at room temperature 
and with gentle stirring. The created LipoNP-CPP molecules were next washed three 
times by spinning down and supernatant replacement with fresh water. To make 
sure that the created construct does not contain agglomerates, LipoNP-CPP were 
next extruded through a membrane of 50 nm pore size. The prepared particles were 
next kept refrigerated. 
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Figure 85. Structure of DLPE. 
 
Preparation of NP-PEG-CPP: Conjugation of HS-PEG-NH2 to AgNPs was carried out, 
based to the protocol described elsewhere184. In summary, 60 µL of 20 nm AgNPs 
were diluted in 440 H2O. 4.7 mg of HS-PEG-NH2 was dissolved in 500 µL of water, 
sonicated for 15 minutes and combined with NPs suspension, by dropwise-addition 
under vigorous stirring. The solution was allowed to react for 1 h in room 
temperature. To remove the HS-PEG-NH2 excess and exchange the water into 50 
mM phosphate buffer, the particles were next passed through polyacrylamide 
desalting column (D-Salt, Polyacrlylamide 6000, 5 ml; Pierce) following 
manufacturer instructions. Approximately 1 ml solution of PEG-covered particles 
was collected. To achieve around 10-fold molar excess of the cross-linker to amine 
groups on NPs, 5 mg of sulfo-SMCC were dissolved in 100 µL 50 mM phosphate 
buffer and added to the NP-PEG-NH2 solution. The reaction was allowed for 30 
minutes at room temperature.  To remove unreacted cross-linker the particles 
were, again, passed through polyacrylamide desalting column. Approximately 1 ml 
of nanoparticle containing solution was collected. Finally, to the particle suspension 
CPP-Cys was added (from a prior prepared stock solution containing T-CEP) the final 
concentration of 10 µM peptide in the solution. After 2 hours of incubation at room 
temperature, the excess peptide was removed by passing the sample through 
the polyacrylamide desalting column. To make sure that the created construct does 
not contain agglomerates, NP-PEG-CPP were extruded through a 50 nm pore size 
membrane. Lastly, the created NP-PEG-CPP molecules were concentrated by 
spinning down (30 min at 10k rpm) and excess buffer removal. The prepared 
particles were kept refrigerated.   
 
Preparation of NP-CPP: 60 µL of 20 nm AgNPs were added to 940 µL of 10 µM CPP-
Cys solution (prepared from the prior stock containing T-CEP). The peptide was 
allowed to react with NPs for 1 h at room temperature, with gentle shaking.  To 
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remove CPP-Cys excess sample was spun down (30 min at 10k rpm) and the NP 
pellet was washed three times with phosphate buffer. The NP-CPP conjugates were 
next sonicated for 15 minutes. The prepared particles were kept refrigerated.   
 
NP concentration determination was performed by anodic stripping voltammetry 
(ASV) on an electrochemical workstation (AutoLab PGSTAT 12, Windsor Scientific), 
with the use of disposable, screen-printed carbon three-electrode sensors (provided 
by LIRANS, University of Bedfordshire), printed with C2000802D2 carbon ink and 
D60202D1 blue dielectric (Gwent Electronic Materials). Series of dilutions of 20 nm 
AgNPs ranging from 1 mg/mL to 5 µg/ml were prepared in duplicate. To 45 µl of the 
prepared samples 5 µL of 1M NH4SCN was added and samples were incubated for 1 
h at room temperature. Samples were next placed onto the sensor surface and 
analyses were performed according to the protocol described by Szymanski et al. 
Electroanalysis, 2010185; Analytical signal, corresponding to the amount of charge 
produced during the stripping step, was recorded and calculated by measuring 
the area under the silver oxidation peak. Calculations were made using General 
Purpose Electrochemical System software (GPES 4.9). Based on the obtained values 
of the nanoparticle amount in the reference samples a standard curve was built, 
used further to estimate the concentration of AgNP in working solutions. 
 
Cell transfection with NPs: Human Dermal Fibroblasts (HDFa) (ATCC number PCS-
201-012,), from stock stored in in liquid nitrogen (NPL), were thawed and next 
seeded in 1 cm2 chambers on glass cover slips with 1.5 mL of complete M106 media 
(Gibco) and antibiotics (gentamicin and amphotericin B). Cells incubated at 37°C, 5% 
CO2 until at least 80% coffluency achieved. Next, growth media were removed from 
the cell cultures and replaced with identical media containing nanoparticles or 
nanoparticle conjugates. After 3 h or 6 h of incubation at 37°C, 5% CO2, the solution 
with the excess (non-internalised) particles was removed and cells washed three 
times with 10 mM phosphate buffer.  Finally, 1 ml of 1.5% glutaraldehyde in 10 mM 
phosphate buffer was added to the cells to fix them. That way prepared samples 
were next provided to Mr Bill Cooley (AHVLA, Weybridge, UK) or Mr Mark Turmaine 
(UCL) to be further processed in preparation for TEM imaging.  
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TEM images were taken by Mr Bill Cooley (AHVLA, Weybridge, UK), Mr Mark 
Turmaine (UCL) and Dr Angelo Bella (Bioengineering, NPL, UK) on Jeol 1010 
Transmission Electron microscopes. Images were processed using Image J software. 
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